product
result
biotechnolog
continu
grow
exponenti
rate
expect
even
greater
percentag
drug
develop
area
biolog
worldwid
new
biotech
drug
treatment
develop
includ
antisens
cell
therapi
gene
therapi
monoclon
antibodi
recombin
protein
vaccin
phrma
pharmaceut
biotechnolog
techniqu
core
methodolog
use
today
drug
discoveri
develop
biolog
small
molecul
recombin
dna
technolog
hybridoma
techniqu
major
method
util
pharmaceut
biotechnolog
histor
timelin
everwiden
understand
human
cellular
function
diseas
process
wealth
addit
innov
biotechnolog
continu
develop
order
harvest
inform
found
human
genom
technolog
advanc
provid
better
understand
relationship
genet
biolog
function
unravel
underli
caus
diseas
explor
associ
genom
variat
drug
respons
enhanc
pharmaceut
research
fuel
discoveri
develop
new
novel
biopharmaceut
revolutionari
technolog
addit
biotechnologyrel
techniqu
improv
competit
costli
process
drug
develop
new
medicin
agent
diagnost
medic
devic
technolog
techniqu
describ
chapter
well
establish
commonli
use
applic
biotechnolog
produc
potenti
therapeut
product
develop
includ
clinic
trial
new
techniqu
emerg
rapid
unpreced
pace
full
impact
futur
molecular
medicin
yet
imagin
central
meaning
discuss
pharmaceut
biotechnolog
twentyfi
rst
centuri
healthcar
omic
technolog
complet
human
genom
project
provid
wealth
new
knowledg
research
turn
increasingli
task
convert
dna
sequenc
data
inform
improv
even
revolution
drug
discoveri
see
fig
patientcent
pharmaceut
care
pharmaceut
scientist
pois
take
advantag
scientifi
c
breakthrough
incorpor
stateoftheart
genom
proteom
techniqu
along
associ
technolog
util
bioinformat
metabonomicsmetabolom
epigenom
system
biolog
pharmacogenom
toxicogenom
glycom
chemic
genom
new
drug
discoveri
develop
clinic
translat
paradigm
addit
techniqu
biotechnolog
molecular
biolog
rapidli
exploit
bring
new
drug
market
topic
introduc
chapter
intent
author
detail
everi
biotechnolog
techniqu
exhaust
sinc
numer
special
resourc
alreadi
meet
need
rather
chapter
illustr
enumer
variou
biotechnolog
key
interest
pharmaci
student
practic
pharmacist
pharmaceut
scientist
effect
mani
aspect
pharmaci
drug
discoveri
drug
develop
sinc
discoveri
dna
overal
structur
world
scientifi
c
commun
rapidli
gain
detail
knowledg
genet
inform
encod
dna
cell
organ
today
begin
person
inform
biotechnolog
techniqu
produc
novel
therapeut
wealth
inform
mechan
variou
diseas
cancer
genet
molecular
level
yet
etiolog
complex
diseas
obes
heart
diseas
remain
poorli
understood
recent
howev
research
util
excit
groundbreak
omic
technolog
work
close
clinician
begun
make
seriou
progress
toward
molecularlevel
understand
etiolog
complex
diseas
clearli
identifi
actual
mani
genet
differ
diseas
call
singl
name
cancer
diabet
depress
etc
later
chapter
explor
concept
phenotyp
import
human
diseas
manifest
complex
phenotyp
result
genet
environment
factor
larg
part
answer
hidden
unknown
human
genom
despit
increas
knowledg
dna
structur
function
genom
entir
collect
gene
function
nonfunct
dna
sequenc
nucleu
organ
yet
sequenc
dna
may
well
largest
natur
occur
molecul
known
success
meet
challeng
sequenc
entir
human
genom
one
histori
great
scientifi
c
achiev
herald
enorm
potenti
venter
et
al
intern
human
genom
sequenc
consortium
genet
code
transcript
translat
known
year
sequenc
human
genom
provid
blueprint
human
protein
sequenc
regulatori
element
govern
development
interpret
genom
potenti
signifi
canc
includ
identifi
genet
determin
common
rare
diseas
provid
methodolog
diagnosi
suggest
interest
new
molecular
site
intervent
see
fig
develop
new
biotechnolog
bring
erad
unlock
secret
human
genom
may
lead
paradigm
shift
clinic
practic
toward
true
target
molecular
medicin
better
diseas
taxonomi
patientperson
therapi
term
genom
comprehens
analysi
understand
dna
structur
function
broadli
refer
analysi
gene
within
genom
organ
sequenc
human
genom
genom
organ
led
enhanc
understand
dna
structur
function
also
fundament
understand
human
biolog
diseas
complex
complic
journey
dna
sampl
dna
sequenc
store
databas
multitud
technolog
approach
along
impress
enhanc
instrument
comput
employ
sequenc
genom
dna
faster
less
expens
mani
industri
analyst
predict
tripl
pharmaceut
r
product
due
sequenc
human
genom
nextgener
genom
sequenc
technolog
quest
genom
move
genom
technolog
effect
clinic
davi
likewis
fi
eld
genom
fundament
impact
modern
drug
discoveri
develop
valid
viabl
drug
target
identifi
ed
genom
challeng
great
progress
occur
yang
et
al
matter
whether
better
understand
diseas
improv
drug
discoveri
genom
revolut
foundat
explos
omic
technolog
fi
nd
applic
research
address
poorli
treat
neglect
diseas
genet
analysi
initi
focus
area
structur
genom
essenti
character
macromolecular
structur
genom
util
comput
tool
theoret
framework
structur
genom
intersect
techniqu
dna
sequenc
clone
pcr
protein
express
crystallographi
big
data
analysi
focus
physic
aspect
genom
construct
analysi
gene
sequenc
gene
map
propos
late
publicli
fund
human
genom
project
hgp
human
genom
initi
hgi
offici
sanction
octob
map
structur
sequenc
human
dna
us
doe
describ
tabl
hgp
structur
genom
envis
proceed
increas
level
genet
resolut
detail
human
genet
linkag
map
approxim
megabas
pair
mb
million
base
pair
resolut
complet
physic
map
mb
resolut
ultim
complet
dna
sequenc
approxim
three
billion
base
pair
pair
chromosom
human
cell
nucleu
base
pair
bp
resolut
project
complet
goal
project
learn
contain
genet
code
also
mine
genom
inform
cure
help
prevent
estim
genet
diseas
affl
ict
humankind
project
would
identifi
approxim
gene
human
dna
determin
base
pair
sequenc
store
inform
databas
creat
new
tool
improv
exist
tool
data
analysi
address
ethic
legal
societ
issu
elsi
may
aris
project
earlier
project
mileston
genom
scienc
reach
june
research
privat
fund
celera
genom
publicli
fund
intern
human
genom
sequenc
consortium
intern
collabor
associ
hgp
jointli
announc
complet
sequenc
human
genom
journal
scienc
rate
map
human
genom
breakthrough
year
decemb
issu
two
group
publish
result
venter
et
al
genom
intern
sequenc
consortium
research
group
employ
origin
cloningbas
sanger
techniqu
dna
sequenc
approxim
year
old
genom
dna
sequenc
approach
hgp
celera
genom
differ
hgp
util
nest
shotgun
approach
human
dna
sequenc
chop
segment
ever
decreas
size
segment
put
rough
order
dna
segment
divid
blast
smaller
fragment
small
fragment
individu
sequenc
sequenc
fragment
assembl
accord
known
rel
order
celera
research
employ
whole
shotgun
approach
broke
whole
genom
small
fragment
fragment
sequenc
assembl
order
identifi
overlap
two
sequenc
approach
requir
unpreced
comput
resourc
fi
eld
bioinformat
describ
later
chapter
regardless
genom
sequenc
strategi
collect
result
impress
million
highqual
sequenc
read
provid
fi
vefold
coverag
entir
human
genom
genom
studi
identifi
ed
one
million
singlenucleotid
polymorph
snp
binari
element
genet
variabl
snp
describ
later
chapter
origin
estim
number
human
gene
genom
vari
consist
genom
research
unveil
number
far
short
biologist
predict
venter
et
al
intern
human
genom
sequenc
consortium
within
month
other
suggest
human
genom
project
goal
detail
genet
linkag
map
mb
comment
poorest
resolut
depict
rel
chromosom
locat
dna
marker
gene
marker
space
chromosom
complet
physic
map
mb
comment
instead
rel
distanc
marker
map
actual
physic
distanc
base
pair
marker
lower
resolut
actual
observ
chromosom
band
microscop
higher
resolut
restrict
map
gener
presenc
restrict
enzym
complet
dna
sequenc
bp
comment
ultim
goal
determin
base
sequenc
gene
marker
found
map
techniqu
along
segment
entir
genom
techniqu
commonli
use
includ
dna
amplifi
cation
method
clone
pcr
techniqu
describ
chap
along
novel
sequenc
bioinformat
techniqu
mb
megabas
million
base
pair
bp
base
pair
human
genom
possess
gene
wright
et
al
approxim
gene
often
cite
number
lee
et
al
nextgener
genom
sequenc
ng
genom
full
spectrum
human
genet
variat
rang
larg
chromosom
chang
singl
base
pair
alter
challeng
genom
scientist
discov
full
extent
genom
structur
variat
refer
genotyp
variat
genet
code
may
associ
encod
trait
trait
display
organ
phenotyp
wish
use
littl
dna
materi
possibl
short
time
least
cost
import
characterist
use
pointofcar
clinic
technolog
discoveri
genotyp
structur
variat
core
understand
diseas
associ
well
identifi
possibl
new
drug
target
alkan
et
al
dna
sequenc
effi
cienci
facilit
studi
decad
sinc
complet
hgp
sequenc
effi
cienci
increas
approxim
cost
singl
genom
sequenc
decreas
nearli
million
recent
treangen
salzberg
move
toward
lowcost
highthroughput
sequenc
essenti
implement
genom
person
medicin
like
alter
futur
clinic
landscap
nextgener
genom
sequenc
methodolog
differ
origin
cloningbas
sanger
techniqu
highthroughput
imagingbas
system
vastli
increas
speed
data
output
clear
defi
nition
nextgener
genom
sequenc
also
known
gener
ng
character
direct
parallel
sequenc
larg
number
amplifi
ed
fragment
dna
without
vectorbas
clone
fragment
dna
tend
sequenc
read
base
pair
numer
exampl
singlemolecul
techniqu
util
commerci
avail
dna
sequenc
cherf
et
al
woollard
et
al
earli
dna
sequenc
compani
illumina
life
technolog
announc
new
product
sequenc
entir
human
genom
day
approxim
businessweek
function
genom
subfi
eld
genom
attempt
answer
question
function
specifi
c
dna
sequenc
level
transcript
translat
ie
gene
rna
transcript
protein
product
raghavachari
research
relat
genom
sequenc
data
determin
structur
genom
observ
biolog
function
predict
fuel
new
drug
discoveri
thorough
better
understand
gene
regul
direct
relationship
gene
activ
dna
sequenc
inform
rare
provid
defi
nitiv
inform
function
regul
particular
gene
genom
sequenc
function
genom
approach
next
step
knowledg
chain
identifi
function
gene
product
potenti
biotech
drug
lead
new
drug
discoveri
target
see
fig
relat
function
genom
therapeut
clinic
outcom
human
genom
sequenc
must
reveal
thousand
genet
variat
among
individu
becom
associ
diseas
symptom
patient
lifetim
sequenc
alon
solut
simpli
end
begin
genom
medicin
era
determin
gene
function
organ
open
door
link
diseas
specifi
c
gene
protein
becom
target
new
drug
method
detect
organ
ie
new
diagnost
agent
andor
biomark
presenc
chang
gene
express
profi
le
correl
risk
progress
suscept
diseas
success
function
genom
facilit
abil
observ
clinic
problem
take
benchtop
structur
function
genom
analysi
return
person
solut
bedsid
form
new
therapeut
intervent
medicin
face
biolog
chang
forev
sequenc
genom
numer
organ
biotechnolog
appli
sequenc
human
genom
also
util
sequenc
genom
compar
simpl
organ
well
mammal
often
protein
encod
genom
simpl
organ
regul
gene
close
resembl
protein
gene
regul
human
sequenc
entir
genom
realiti
chore
sort
human
pathogen
organ
divers
factor
correl
genom
data
provid
real
pharmaceut
benefi
ts
activ
area
research
compar
genom
fi
eld
genom
studi
relationship
genom
structur
function
across
differ
biolog
speci
strain
thu
provid
inform
evolutionari
process
act
upon
genom
raghavachari
compar
genom
exploit
similar
differ
regulatori
region
gene
well
rna
protein
differ
organ
infer
select
act
upon
element
sinc
model
organ
much
easier
maintain
laboratori
set
research
activ
pursu
compar
genom
studi
multipl
organ
unlock
genom
data
organ
provid
valuabl
insight
molecular
basi
inherit
human
diseas
cerevisia
yeast
good
model
studi
cancer
common
organ
use
rdna
methodolog
exampl
becom
well
known
women
inherit
gene
mutat
gene
high
risk
perhap
high
develop
breast
cancer
age
petrucelli
et
al
fi
rst
diagnost
product
gener
genom
data
test
breast
cancer
predisposit
gene
product
wellcharacter
protein
implic
breast
ovarian
cancer
evid
accumul
suggest
protein
cerevisia
distantli
signifi
cantli
relat
protein
fruit
fl
possess
gene
similar
human
tumor
suppressor
gene
studi
c
elegan
unseg
vermiform
provid
much
earli
knowledg
apoptosi
normal
biolog
process
program
cell
death
greater
protein
identifi
ed
thu
far
common
laboratori
anim
mous
structur
similar
known
human
protein
similarli
map
whole
human
cancer
cell
genom
pinpoint
gene
involv
cancer
aid
understand
cell
chang
treatment
human
malign
util
techniqu
function
compar
genom
collin
barker
cancer
cell
small
chang
dna
sequenc
caus
cell
make
protein
nt
allow
cell
function
protein
make
cell
grow
quickli
caus
damag
neighbor
cell
becom
cancer
genom
cancer
cell
also
use
stratifi
cancer
cell
identifi
one
type
cancer
anoth
identifi
subtyp
cancer
within
type
breast
cancer
understand
cancer
genom
step
toward
person
oncolog
numer
project
underway
around
world
two
project
includ
us
nih
cancer
genom
atla
project
us
nih
sanger
institut
cancer
genom
project
sanger
institut
compar
genom
use
provid
compil
gene
code
protein
essenti
growth
viabil
pathogen
organ
yet
differ
human
protein
cf
chap
exampl
worldwid
effort
rapidli
sequenc
sever
acut
respiratori
syndrom
sar
associ
coronaviru
genom
speed
diagnosi
prevent
pandem
guid
vaccin
creation
great
use
genom
infecti
diseas
ng
like
provid
opportun
place
genom
directli
clinic
enabl
infecti
diseas
pointofcar
applic
thu
select
superior
patient
outcom
also
genom
mine
new
target
drug
design
use
genom
techniqu
may
aid
quest
new
antibiot
clinic
environ
increas
incid
antibiot
resist
valuabl
resourc
perform
function
compar
genom
biobank
collect
biolog
sampl
refer
purpos
repositori
type
also
might
refer
biorepositori
name
type
tissu
depend
exact
type
specimen
ie
tissu
bank
genom
techniqu
foster
creation
dna
bank
collect
storag
analysi
hundr
thousand
specimen
contain
analyz
dna
nucleat
cell
includ
cell
blood
hair
follicl
buccal
swab
cancer
biopsi
urin
specimen
suitabl
dna
sampl
analysi
present
later
date
dna
bank
prove
valuabl
tool
genet
research
thornton
et
al
broadest
sens
repositori
could
incorpor
collect
plant
anim
sampl
develop
biobank
world
devot
research
variou
type
cancer
dna
bank
devot
cancer
research
grown
fastest
also
almost
explos
growth
biobank
special
research
autism
schizophrenia
heart
diseas
diabet
mani
diseas
structur
genom
function
genom
proteom
pharmacogenom
omic
technolog
gener
enorm
volum
genet
biochem
data
store
analyz
live
era
faster
comput
bigger
better
data
storag
improv
method
data
analysi
led
bioinform
superhighway
facilit
omic
revolut
scientist
appli
advanc
inform
technolog
innov
softwar
algorithm
massiv
parallel
comput
ongo
research
biotechnolog
area
genom
give
birth
fast
grow
fi
eld
bioinformat
lengauer
hartmann
singh
somvanshi
integr
new
technolog
comput
approach
domain
bioinformat
essenti
acceler
rate
discoveri
new
breakthrough
improv
health
wellb
patient
care
bioinformat
applic
comput
technolog
biolog
scienc
object
discov
knowledg
bioinformat
research
better
exploit
tremend
fl
ood
genom
proteom
data
costeffect
data
mine
drug
discoveri
needl
massiv
data
haystack
case
data
mine
refer
bioinformat
approach
sift
volum
raw
data
identifi
extract
relev
inform
develop
use
relationship
among
modern
drug
discoveri
commensur
need
better
understand
defi
ne
diseas
util
bioinformat
techniqu
gather
inform
multipl
sourc
hgp
function
genom
studi
proteom
phenotyp
patient
medic
record
bioassay
result
includ
toxicolog
studi
integr
data
appli
life
scienc
develop
algorithm
gener
use
target
identifi
cation
drug
lead
identifi
cation
data
seen
fig
hierarchi
inform
collect
goe
well
beyond
biodata
contain
genet
code
transcrib
translat
recent
nation
research
council
report
us
nation
academi
entitl
toward
precis
medicin
build
knowledg
network
biomed
research
new
taxonomi
diseas
call
new
data
network
integr
emerg
research
molecular
basi
diseas
clinic
data
individu
patient
drive
develop
accur
taxonomi
diseas
ultim
improv
diseas
diagnosi
patient
outcom
us
nation
academi
report
note
challeng
includ
scientifi
c
technic
advanc
need
correl
genet
environment
fi
nding
incid
diseas
legal
ethic
challeng
privaci
issu
electron
health
record
ehr
etc
entir
encod
human
dna
sequenc
alon
requir
comput
storag
approxim
bit
inform
equival
thousand
book
genbank
manag
nation
center
biotechnolog
inform
ncbi
nation
institut
health
european
molecular
biolog
laboratori
embl
dna
data
bank
japan
ddbj
three
mani
center
worldwid
collabor
collect
nucleic
acid
sequenc
databank
public
privat
store
ten
million
sequenc
wu
et
al
store
analyz
volum
data
ie
compar
relat
inform
variou
sourc
identifi
use
andor
predict
characterist
trend
select
group
drug
target
protein
human
bodi
present
herculean
task
approach
potenti
chang
fundament
way
basic
scienc
conduct
valid
biolog
conclus
reach
bioinformat
multifacet
implement
may
thought
techniqu
electron
biolog
ebiolog
conceptu
biolog
silico
biolog
comput
biolog
datadriven
tool
integr
bioinformat
function
knowledg
complex
biolog
system
studi
remain
critic
foundat
omic
technolog
describ
follow
profess
pharmaci
readili
recogn
optim
patientcent
care
requir
effect
integr
drug
inform
patient
inform
system
known
pharmaci
informat
anderson
et
al
patient
inform
includ
data
genom
proteom
individu
patient
characterist
patient
safeti
evidencebas
medicin
electron
health
record
drug
inform
includ
found
primari
literatur
drug
inform
databas
internet
resourc
hospit
inform
system
pharmaci
inform
system
drug
discoveri
literatur
pharmacogenom
studi
beyond
scope
chapter
explor
pharmaci
informat
becom
import
area
pharmacist
knowledg
fox
rememb
central
dogma
molecular
biolog
dna
rna
via
process
transcript
rna
protein
via
process
translat
transcriptom
collect
rna
transcrib
element
given
genom
collect
transcript
subsequ
translat
protein
mrna
noncod
transcript
noncod
microrna
mirna
part
transcriptom
cf
chap
transcriptom
repres
small
part
genom
instanc
challeng
modern
biolog
captur
integr
inform
hierarchi
level
bioinformat
provid
need
resourc
meet
challeng
human
genom
lu
et
al
term
transcript
omic
refer
omic
technolog
examin
complex
rna
transcript
organ
varieti
intern
extern
condit
refl
ect
gene
activ
express
given
time
except
mrna
degrad
phenomena
transcript
attenu
subramanian
et
al
therefor
transcriptom
vari
extern
environment
condit
genom
roughli
fi
xed
given
cell
line
exclud
mutat
transcriptom
stem
cell
cancer
cell
particular
interest
better
understand
process
cellular
differenti
carcinogenesi
highthroughput
techniqu
base
microarray
technolog
use
examin
express
level
mrna
given
cell
popul
proteom
studi
organ
complet
complement
protein
proteom
seek
defi
ne
function
correl
express
profi
le
protein
encod
within
organ
genom
proteom
veenstra
function
genom
research
provid
unpreced
inform
resourc
studi
biochem
pathway
molecular
level
certainli
vast
array
approxim
gene
identifi
ed
sequenc
human
genom
shown
function
import
variou
diseas
state
see
druggabl
genom
discuss
key
identifi
ed
protein
serv
potenti
new
site
therapeut
intervent
see
fig
applic
function
proteom
process
drug
discoveri
creat
fi
eld
research
refer
pharmacoproteom
tri
compar
whole
protein
profi
le
healthi
person
versu
patient
diseas
analysi
may
point
new
novel
target
drug
discoveri
person
medicin
dalessandro
zolla
transcript
translat
approxim
human
gene
produc
hundr
thousand
protein
due
posttranscript
regul
posttransl
modifi
cation
protein
product
number
type
concentr
may
vari
depend
cell
tissu
type
diseas
state
factor
protein
function
depend
primari
secondari
tertiari
structur
protein
molecul
interact
less
year
old
concept
proteom
requir
determin
structur
biochem
physiolog
repertoir
protein
proteom
greater
scientifi
c
challeng
genom
due
intricaci
protein
express
complex
protein
structur
structur
proteom
relat
biolog
activ
function
proteom
protein
express
isol
purifi
cation
identifi
cation
character
among
key
procedur
util
proteom
research
perform
procedur
technolog
platform
gel
electrophoresi
mass
spectrometri
chipbas
microarray
discuss
later
chapter
xray
crystallographi
protein
nuclear
magnet
reson
nmr
phage
display
employ
initi
human
proteom
organ
hupo
complet
fi
rst
largescal
studi
character
human
serum
plasma
protein
ie
human
serum
plasma
proteom
state
et
al
spent
past
year
develop
strategi
fi
rst
phase
human
proteom
project
paik
et
al
intern
consortium
chromosomecentr
human
proteom
project
attempt
defi
ne
entir
set
encod
protein
human
chromosom
paik
et
al
pharmaceut
scientist
anticip
mani
protein
identifi
ed
proteom
research
entir
novel
possess
unknown
function
scenario
offer
uniqu
opportun
identifi
previous
unknown
molecular
target
also
develop
new
biomark
ultrasensit
diagnost
address
unmet
clinic
need
veenstra
today
methodolog
allow
us
identifi
valid
drug
target
new
diagnost
methodolog
simpli
examin
gene
sequenc
inform
howev
silico
proteom
computerbas
predict
protein
structur
intermolecular
interact
function
current
activ
area
research
often
multipl
gene
protein
product
involv
singl
diseas
process
sinc
protein
act
alon
studi
protein
interact
paramount
full
understand
function
also
mani
abnorm
cell
function
may
result
overexpress
gene
andor
protein
underexpress
gene
protein
gene
mutat
caus
malform
protein
posttransl
modifi
cation
chang
alter
protein
function
therefor
real
valu
human
genom
sequenc
data
realiz
everi
protein
code
approxim
gene
function
assign
biochip
known
dna
microarray
oligonucleotid
microarray
surfac
collect
hundr
thousand
immobil
nucleic
acid
sequenc
oligonucleotid
grid
creat
special
equip
simultan
examin
conduct
express
analysi
amaratunga
et
al
semizarov
biochip
may
contain
repres
particular
set
gene
sequenc
ie
sequenc
code
human
cytochrom
isozym
may
contain
sequenc
repres
gene
organ
produc
massiv
amount
genet
inform
semizarov
vitro
diagnost
market
diffi
cult
enter
roch
diagnost
amplichip
cyp
fdaapprov
diagnost
tool
abl
determin
patient
genotyp
respect
two
gene
govern
drug
metabol
inform
obtain
may
use
physician
select
appropri
drug
andor
dosag
given
patient
area
cardiovascular
diseas
high
blood
pressur
depress
other
accord
compani
commonli
array
prepar
nonpor
support
glass
microscop
slide
dna
microarray
gener
contain
highdens
microspot
cdna
sequenc
approxim
kb
length
repres
thousand
gene
fi
eld
advanc
signifi
cantli
technolog
develop
synthes
close
space
oligonucleotid
glass
wafer
use
semiconductori
industri
photolithograph
mask
techniqu
see
fig
oligonucleotid
microarray
often
call
oligonucleotid
array
dna
chip
contain
close
space
synthet
genespecifi
c
oligonucleotid
repres
thousand
gene
sequenc
microarray
provid
express
analysi
mrna
screen
dna
variat
also
possibl
thu
biochip
provid
polymorph
detect
genotyp
well
hybridizationbas
express
monitor
semizarov
microarray
analysi
gain
increas
signifi
canc
direct
result
genom
sequenc
studi
array
technolog
logic
tool
studi
function
genom
sinc
result
obtain
may
link
function
express
microarray
technolog
potenti
studi
key
area
molecular
medicin
drug
discoveri
unlimit
stage
develop
exampl
gene
express
level
thousand
mrna
speci
may
studi
simultan
normal
versu
cancer
cell
incub
potenti
anticanc
drug
candid
relat
microarray
technolog
includ
protein
microarray
tissu
microarray
cell
microarray
also
call
transfect
microarray
chemic
compound
microarray
antibodi
microarray
principl
immobil
collect
differ
accordingli
biomark
clinic
relev
biolog
featur
use
indic
biolog
state
diseas
predisposit
diseas
diseas
progress
diseas
regress
deprimo
detect
concentr
chang
biomark
may
indic
particular
diseas
state
eg
presenc
certain
antibodi
may
indic
infect
physiolog
toxic
chang
express
state
protein
biomark
may
correl
risk
progress
diseas
suscept
diseas
given
treatment
drug
safeti
profi
le
implement
form
medic
devic
measur
biomark
becom
vitro
diagnost
tool
william
et
al
well
beyond
chapter
provid
detail
discuss
biomark
import
note
omic
technolog
includ
omicen
technolog
microarray
develop
clinic
measur
devic
biomark
biomark
enabl
character
patient
popul
undergo
clinic
trial
drug
therapi
may
acceler
drug
develop
modern
drug
discoveri
often
simultan
involv
biomark
discoveri
diagnost
develop
frank
hargreav
drug
develop
scientist
hope
develop
appropri
biomark
facilit
go
go
decis
potenti
therapeut
agent
develop
process
pritchard
jurimaromet
biomark
discoveri
close
tie
applic
genom
previous
describ
chapter
indic
normal
biolog
process
pathogen
process
pharmacolog
respons
therapeut
intervent
biomark
may
serv
substitut
clinic
end
point
thu
surrog
end
point
semizarov
biomark
avail
wide
rang
diseas
condit
includ
alzheim
parkinson
diseas
maetzler
berg
cardiac
injuri
mclean
huang
lung
injuri
kodavanti
druginduc
liver
injuri
ozer
et
al
acut
kidney
injuri
dieterl
sistar
immunotox
dietert
variou
cancer
kelloff
sigman
pediatr
care
goldman
et
al
host
diseas
biolog
condit
theranost
rapid
diagnost
possibl
microarray
measur
clinic
signifi
cant
biomark
may
identifi
patient
like
benefi
harm
new
medic
warner
bundl
new
drug
like
develop
parallel
drug
theranost
diagnosi
requisit
biomark
eg
overexpress
gene
product
certain
breast
cancer
patient
infl
uenc
physician
therapeut
decis
ie
prescrib
drug
trastuzumab
herceptin
receptorposit
breast
cancer
patient
thu
diagnost
therapi
distinctli
coupl
theranost
theranost
predict
clinic
success
drug
exampl
use
introduc
concept
theranost
possibl
best
exampl
person
medicin
see
later
chapter
achiev
best
medic
outcom
choos
treatment
work
well
person
genom
profi
le
certain
characterist
metabolom
consist
complet
set
small
molecul
involv
energi
transmiss
cell
interact
biolog
molecul
follow
metabol
pathway
metabolit
may
metabol
intermedi
hormon
signal
molecul
secondari
metabolit
nicholson
wilson
patti
et
al
techniqu
process
identifi
clinic
signific
biomark
human
diseas
drug
safeti
foster
systemat
studi
uniqu
chemic
fi
ngerprint
specifi
c
cellular
process
leav
behind
specifi
calli
small
molecul
metabolit
profi
le
januari
scientist
univers
alberta
univers
calgari
fi
nish
draft
human
metabolom
wishart
et
al
catalogu
character
metabolit
drug
food
compon
found
human
bodi
thu
genom
proteom
tell
whole
stori
might
happen
within
cell
metabol
profi
ling
give
instantan
snapshot
physiolog
cell
highperform
liquid
chromatographi
coupl
sophist
nuclear
magnet
reson
nmr
mass
spectrometri
ms
techniqu
use
separ
quantifi
complex
metabolit
mixtur
found
biolog
fl
uid
get
pictur
metabol
continuum
organ
infl
uenc
intern
extern
environ
fi
eld
metabonom
holist
studi
metabol
continuum
equival
level
studi
genom
proteom
howev
unlik
genom
proteom
microarray
technolog
littl
use
sinc
molecul
assay
metabonom
small
molecul
end
product
gene
express
result
protein
function
term
metabolom
arisen
metabol
composit
cell
specifi
ed
time
wherea
metabonom
includ
static
metabolit
composit
concentr
fulltim
cours
fl
uctuat
coupl
inform
collect
biobank
larg
collect
patient
biolog
sampl
medic
record
metabonom
metabolom
studi
detect
given
metabolit
level
increas
decreas
may
reliabl
predict
onset
diseas
recent
research
discoveri
oncolog
led
reconsider
regard
metabol
dysfunct
cancer
cell
prolifer
differenti
metabolom
studi
may
abl
interrog
cancer
cell
oxid
stress
lead
caus
genet
instabl
underpin
carcinogenesi
therefor
indic
window
life
cancer
cell
optim
therapeut
intervent
dalessandro
zolla
also
techniqu
fi
nding
use
drug
safeti
screen
identifi
cation
clinic
biomark
system
biolog
studi
see
note
decad
patient
respons
administr
drug
highli
variabl
within
divers
patient
popul
effi
caci
determin
clinic
trial
base
upon
standard
dose
rang
deriv
larg
popul
studi
better
understand
molecular
interact
occur
within
pharmacokinet
phase
drug
action
coupl
new
genet
knowledg
genom
knowledg
human
advanc
us
closer
ration
mean
optim
drug
therapi
optim
respect
patient
genotyp
ensur
maximum
effi
caci
minim
advers
effect
goal
environ
diet
age
lifestyl
state
health
infl
uenc
person
respons
medicin
understand
individu
genet
makeup
thought
key
creat
person
drug
greater
effi
caci
safeti
approach
relat
pharmacogenet
pharmacogenom
promis
advent
person
medicin
drug
drug
combin
optim
individu
uniqu
genet
makeup
chapter
serv
introduct
entir
class
offer
mani
book
review
articl
written
pharmacogenet
pharmacogenom
lindpaint
knoell
sade
grossman
goldstein
zdanowicz
pirmoham
brazeau
brazeau
compar
base
sequenc
dna
two
individu
reveal
approxim
ident
base
differ
polymorph
scatter
throughout
genom
bestcharacter
human
polymorph
singlenucleotid
polymorph
snp
occur
approxim
everi
base
three
billion
base
pair
human
genom
kassam
et
al
dna
sequenc
variat
singl
nucleotid
c
g
genom
differ
member
speci
pair
chromosom
individu
exampl
two
sequenc
dna
fragment
differ
individu
aagttc
c
ta
aagttc
ta
contain
differ
singl
nucleotid
commonli
refer
snip
subtl
sequenc
variat
account
genet
differ
observ
among
human
thu
util
determin
inherit
gene
success
gener
technolog
avail
sever
compani
allow
genotyp
hundr
thousand
snp
typic
coupl
day
research
suggest
gener
human
toler
snp
probabl
surviv
mechan
toler
may
result
snp
occur
noncod
region
genom
identifi
snp
occur
gene
code
region
csnp
andor
regulatori
sequenc
may
hold
key
elucid
complex
polygen
diseas
cancer
heart
diseas
diabet
understand
differ
respons
drug
therapi
observ
individu
patient
grossman
goldstein
pirmoham
us
doe
csnp
result
amino
acid
substitut
gene
protein
product
due
degeneraci
genet
code
csnp
refer
synonym
csnp
csnp
known
nonsynonym
produc
conserv
amino
acid
chang
similar
side
chain
charg
size
signifi
cant
amino
acid
substitut
snp
caus
diseas
presenc
help
determin
likelihood
individu
may
develop
particular
diseas
maladi
snp
associ
epidemiolog
patholog
data
use
track
suscept
common
diseas
cancer
heart
diseas
diabet
davidson
mcinerney
biomed
research
recogn
discov
snp
link
diseas
lead
potenti
identifi
cation
new
drug
target
diagnost
test
identifi
cation
map
hundr
thousand
snp
use
largescal
associ
studi
may
turn
snp
biomark
diseas
andor
drug
respons
genet
factor
snp
believ
like
infl
uenc
etiolog
diseas
hypertens
diabet
lipidemia
directli
via
effect
known
risk
factor
davidson
mcinerney
exampl
chronic
metabol
diseas
type
diabet
strong
associ
obes
pathogenesi
includ
defect
secret
peripher
action
insulin
associ
type
diabet
snp
three
gene
detect
addit
cluster
new
variant
chromosom
howev
herit
valu
rang
type
diabet
obvious
heterogen
diseas
etiolog
clinic
thu
snp
overwhelm
major
case
like
indic
diseas
develop
project
impact
snp
understand
human
diseas
led
format
snp
consortium
intern
research
collabor
involv
pharmaceut
compani
academ
laboratori
privat
support
usa
doe
nih
human
genom
program
help
establish
goal
identifi
map
snp
goal
includ
develop
rapid
largescal
technolog
snp
identifi
cation
identifi
cation
common
variant
code
region
identifi
ed
gene
creation
snp
map
least
element
may
serv
futur
biomark
develop
knowledg
aid
futur
studi
sequenc
variat
creation
public
resourc
dna
sampl
cell
line
databas
us
doe
snp
databas
includ
databas
snp
consortium
tsc
dbsnp
databas
nation
center
biotechnolog
inform
ncbi
human
genom
variat
databas
hgvbase
simplest
term
pharmacogenom
whole
genom
applic
pharmacogenet
examin
singl
gene
interact
drug
tremend
advanc
biotechnolog
caus
dramat
shift
way
new
pharmaceut
discov
develop
monitor
patient
use
pharmacist
util
knowledg
gain
genom
proteom
tailor
drug
therapi
meet
need
individu
patient
employ
fi
eld
pharmacogenet
pharmacogenom
kalow
knoell
sade
grossman
goldstein
zdanowicz
pirmoham
brazeau
brazeau
pharmacogenet
studi
individu
genet
differ
infl
uenc
drug
action
usag
dose
detail
knowledg
patient
pharmacogenet
relat
particular
drug
therapi
may
lead
enhanc
effi
caci
greater
safeti
pharmacogenet
analysi
may
identifi
respons
patient
popul
prior
administr
ie
person
medicin
fi
eld
pharmacogenet
year
old
undergo
renew
exponenti
growth
time
particular
interest
fi
eld
pharmacogenet
understand
genet
infl
uenc
drug
pharmacokinet
profi
le
genet
variat
affect
liver
enzym
ie
cytochrom
group
drug
transport
protein
genet
infl
uenc
drug
pharmacodynam
profi
le
variat
receptor
protein
express
abla
kroetz
frye
johnson
kalow
wang
contrast
pharmacogenom
link
whole
genom
snp
singl
gene
studi
entir
genom
organ
ie
human
patient
express
nonexpress
gene
given
physiolog
state
pharmacogenom
combin
tradit
pharmaceut
scienc
annot
knowledg
gene
protein
singlenucleotid
polymorph
might
view
logic
converg
stepwis
advanc
genom
grow
fi
eld
pharmacogenet
incorrectli
defi
nition
pharmacogenet
pharmacogenom
often
use
interchang
whatev
defi
nition
share
challeng
clinic
translat
move
bench
top
research
bedsid
applic
patient
care
method
genomewid
associ
studi
gwa
also
known
whole
genom
associ
studi
power
tool
identifi
genet
loci
affect
instanc
drug
respons
suscept
advers
drug
reaction
davidson
mcinerney
wu
et
al
studi
examin
mani
genet
variat
found
differ
individu
determin
associ
variant
genotyp
biolog
trait
phenotyp
major
gwa
typic
studi
associ
snp
drug
respons
snp
major
diseas
fi
rst
gwa
publish
emerg
import
tool
per
data
nhgri
gwa
catalog
hundr
thousand
individu
test
human
gwa
examin
diseas
trait
snp
earli
hindroff
et
al
believ
core
driver
vision
person
medicin
gwa
coupl
hapmap
project
intern
effort
identifi
map
region
dna
sequenc
nearli
ident
within
broad
popul
date
plagu
inconsist
genotyp
diffi
culti
assign
phenotyp
overal
qualiti
data
miclau
et
al
wu
et
al
b
c
challeng
includ
difficulti
identifi
key
genet
loci
due
two
gene
small
addit
effect
trait
epistasi
trait
caus
gene
mutat
sever
differ
chromosom
loci
locu
heterogen
environment
caus
modifi
express
trait
respons
trait
undetect
popul
structur
studi
aris
studi
member
share
common
ancestr
heritag
brazeau
brazeau
practic
use
approach
introduct
everyday
clinic
set
remain
challeng
undoubtedli
aid
new
nextgener
sequenc
techniqu
enhanc
bioinformat
capabl
better
genom
understand
much
modern
medic
care
decisionmak
base
upon
observ
success
diagnosi
treatment
larger
popul
level
expect
howev
healthcar
start
undergo
revolutionari
chang
new
genom
omic
technolog
becom
avail
clinic
better
predict
diagnos
monitor
treat
diseas
level
specifi
c
patient
goal
match
individu
patient
effect
safest
drug
dose
directtoconsum
genom
test
becam
readili
avail
navigen
decod
genet
mcguir
et
al
academ
medic
center
begun
demonstr
feasibl
routin
clinic
genotyp
mean
inform
pharmacotherapeut
treatment
select
oncolog
tursz
et
al
likewis
demonstr
project
pharmacogenom
enter
pharmaci
practic
sever
set
koomer
ansong
crew
et
al
padgett
et
al
pharmaci
educ
curricula
evolv
prepar
graduat
practic
person
medicin
environ
lee
et
al
krynetskiy
calligaro
koomer
murphi
et
al
zembl
approach
entir
consist
concept
patientcent
care
improv
patient
outcom
clanci
collin
waldman
terzic
kay
et
al
modern
genom
proteom
metabolom
pharmacogenom
epigenom
discuss
later
chapter
technolog
implement
clinic
faster
less
expens
instrument
methodolog
introduc
identifi
genet
variant
better
inform
healthcar
provid
individu
patient
tailor
evidencebas
medic
treatment
suggest
ration
approach
toward
prevent
care
hope
realiti
person
medicin
sometim
refer
part
molecular
medicin
pharmacotherapi
inform
patient
individu
genom
proteom
inform
global
prioriti
knoell
sade
grossman
goldstein
rahbar
et
al
pharmaceut
biotechnolog
text
limit
discuss
focu
person
medicin
primarili
pharmacogenom
pharmacogenet
context
howev
genomictyp
technolog
includ
gwa
nextgener
sequenc
proteom
metabolom
crucial
success
implement
person
medicin
hope
omic
scienc
bring
predict
optim
drug
select
drug
dosag
assur
safe
effect
pharmacotherapi
fig
discuss
import
recogn
pharmacogenet
pharmacogenom
subtli
differ
brazeau
brazeau
pharmacogenom
introduc
addit
element
present
technic
abil
pinpoint
patientspecifi
c
dna
variat
use
genom
techniqu
area
look
genet
composit
genet
variat
organ
connect
drug
respons
variat
target
pathway
studi
understand
variat
manifest
infl
uenc
respons
overlap
fi
eld
studi
pharmacogenom
much
newer
term
correl
individu
patient
dna
variat
snp
level
variat
knowledg
rather
gene
level
variat
knowledg
respons
pharmacotherapi
person
medicin
employ
technolog
optim
person
medicin
util
pharmacogenom
knowledg
would
spot
diseas
occur
patient
detect
critic
variant
infl
uenc
treatment
increas
drug
effi
caci
upon
pharmacotherapi
reduc
drug
toxic
also
would
facilit
drug
develop
process
see
fig
includ
improv
clinic
develop
outcom
reduc
overal
cost
drug
develop
lead
develop
new
diagnost
test
impact
therapeut
decis
grossman
goldstein
zineh
huang
individu
optim
pharmacotherapi
would
fi
rst
requir
detail
genet
analysi
patient
assembl
comprehens
list
snp
pharmacogenom
test
like
form
microarray
technolog
base
upon
clinic
valid
biomark
would
administ
preidentifi
respons
patient
dose
specifi
c
agent
exampl
microarraybas
diagnost
fdaapprov
amplichip
roch
screen
patient
presenc
snp
infi
niti
multiplex
assay
warfarin
therapi
autogenom
pathwork
tissu
origin
test
common
malign
tumor
type
better
focu
treatment
option
impact
patient
snp
use
new
exist
drug
would
thu
predict
individu
drug
therapi
would
identifi
ed
assur
maxim
effi
caci
minim
toxic
topol
person
medicin
would
also
requir
knowledg
individu
patient
genom
profi
le
help
identifi
potenti
drug
respond
nonrespond
might
accomplish
test
presenc
absenc
critic
biomark
may
associ
predict
respons
rate
us
fda
provid
onlin
list
fdaapprov
drug
pharmacogenom
inform
label
black
box
label
includ
specifi
c
action
taken
base
genet
inform
drug
label
contain
inform
genom
biomark
may
predict
drug
exposur
clinic
respons
rate
risk
advers
reaction
genotypespecifi
c
dose
suscept
specifi
c
mechan
drug
action
polymorph
drug
target
disposit
gene
rather
reproduc
tabl
whole
part
text
reader
may
access
constantli
updat
form
wwwfdagov
r
u
g
c
e
n
c
e
r
e
e
r
c
h
r
e
e
r
c
h
r
e
well
understood
beyond
genom
proteom
patient
behavior
environment
factor
infl
uenc
clinic
outcom
suscept
diseas
emerg
fi
eld
nutrigenom
envirogenom
studi
addit
layer
complex
person
medicin
becom
especi
import
case
cost
test
less
either
cost
drug
cost
correct
advers
drug
reaction
caus
drug
pharmaceut
care
would
begin
identifi
patient
suscept
diseas
administ
right
drug
right
patient
right
time
exampl
monoclon
antibodi
trastuzumab
herceptin
person
breast
cancer
therapi
specifi
calli
target
gene
product
human
breast
cancer
overexpress
human
epiderm
growth
factor
receptor
protein
kolesar
exhibit
reduc
side
effect
compar
standard
chemotherapi
due
protein
target
specifi
citi
trastuzumab
prescrib
treat
breast
cancer
patient
unless
patient
fi
rst
test
posit
overexpress
current
immunohistochem
assay
sophist
dna
microarray
assay
exampl
show
power
futur
test
success
target
therapi
person
medicin
foster
concept
era
blockbust
drug
may
replac
nich
buster
drug
highli
effect
medicin
individu
small
group
respond
patient
identifi
ed
genom
proteom
techniqu
also
numer
articl
predict
pharmacogenom
would
revolution
medicin
initi
predict
live
hype
due
statist
scientifi
c
commerci
hurdl
million
snp
posit
believ
present
human
popul
largescal
detect
genet
variat
hold
key
success
person
medicin
pennisi
reardon
baker
correl
environment
factor
behavior
factor
genom
proteom
factor
includ
pharmacogenom
metabolom
factor
phenotyp
observ
across
larg
popul
remain
daunt
dataintens
challeng
yet
pharmacogenet
pharmacogenom
impact
modern
medicin
genet
variat
associ
drug
metabol
drug
transport
process
result
product
gene
express
metabol
enzym
transport
protein
respect
play
critic
role
determin
concentr
drug
activ
form
site
action
also
site
possibl
toxic
action
thu
pharmacogenet
pharmacogenom
analysi
drug
metabol
drug
transport
import
better
clinic
understand
predict
effect
genet
variat
drug
effect
safeti
abla
kroetz
frye
wang
cox
weston
well
recogn
specifi
c
drug
metabol
phenotyp
may
caus
advers
drug
reaction
instanc
patient
lack
enzymat
activ
form
diminish
level
possess
modifi
ed
version
cytochrom
allel
metabol
certain
class
pharmaceut
agent
differ
patient
express
nativ
activ
enzym
pharmacogenet
polymorph
examin
date
differ
frequenc
among
racial
ethnic
group
exampl
enzym
defi
cienci
may
occur
asian
patient
black
patient
white
patient
frye
diagnost
test
detect
defi
cienci
could
use
identifi
patient
administ
drug
metabol
predominantli
tabl
provid
select
exampl
common
drug
metabol
polymorph
pharmacokinet
consequ
burgeon
understand
genet
warfarin
metabol
warfarin
anticoagul
therapi
becom
leader
pharmacogenet
analysi
pharmacokinet
predict
limdi
retti
momari
crouch
bungard
et
al
mcdonagh
et
al
advers
drug
reaction
adr
warfarin
account
adr
usa
second
digoxin
warfarin
dose
adjust
goal
achiev
inr
intern
normal
ratio
ratio
patient
prothrombin
time
compar
normal
control
clinic
challeng
limit
hemorrhag
primari
adr
achiev
optim
degre
protect
thromboembol
deviat
inr
shown
strongest
risk
factor
bleed
complic
major
rout
metabol
warfarin
compound
identifi
ed
infl
uenc
posit
neg
warfarin
inr
includ
cimetidin
clofi
brate
propranolol
celecoxib
competit
inhibit
fl
uvoxamin
inhibitor
sever
cyp
enzym
variou
antifung
antibiot
eg
miconazol
fl
uconazol
erythromycin
omeprazol
alcohol
ginseng
garlic
research
determin
major
individu
patient
variat
observ
clinic
respons
warfarin
therapi
genet
natur
infl
uenc
genet
variabl
metabol
enzym
vitamin
k
cycl
enzym
possibl
transport
protein
genotyp
polymorph
alon
explain
variabl
observ
warfarin
mainten
dose
figur
show
protein
involv
warfarin
action
indic
pharmacogenom
variant
signifi
cantli
infl
uenc
warfarin
therapi
optim
outcom
studi
basic
research
clinic
level
involv
effect
drug
transport
protein
pharmacokinet
profi
le
drug
abla
kroetz
area
activ
studi
effect
genet
variat
clinic
effect
includ
effl
ux
transport
protein
bioavail
cn
exposur
tumor
resist
neurotransmitt
uptak
transport
valid
drug
target
novel
transport
protein
still
identifi
ed
result
human
genom
project
subsequ
proteom
research
studi
need
character
express
regul
function
properti
known
new
transport
protein
better
assess
potenti
predict
alter
drug
respons
base
transport
genotyp
genom
variat
affect
pharmacokinet
profi
le
drug
also
strongli
infl
uenc
pharmacodynam
profi
le
drug
via
drug
target
understand
complex
drug
respons
factor
infl
uenc
express
protein
target
directli
drug
interact
must
studi
target
includ
drug
receptor
involv
respons
well
protein
associ
diseas
risk
pathogenesi
andor
toxic
includ
infecti
diseas
johnson
roger
webster
increas
number
promin
exampl
inherit
polymorph
infl
uenc
drug
pharmacodynam
follow
warfarin
exampl
see
fig
major
individu
patient
variat
observ
clinic
respons
anticoagul
therapi
genet
natur
howev
genotyp
polymorph
alon
explain
variabl
observ
warfarin
figur
critic
pharmacogenom
variant
affect
warfarin
drug
action
adr
genom
omic
technolog
mainten
dose
warfarin
effect
also
infl
uenc
genet
variabl
vitamin
k
cycl
enzym
drug
receptor
warfarin
gener
recogn
vitamin
k
epoxid
reductas
enzym
recycl
vitamin
k
coagul
cascad
vitamin
k
epoxid
reductas
determin
highli
variant
much
clinic
variabl
observ
warfarin
result
polymorph
enzym
associ
implic
drug
respons
genet
variat
target
varieti
drug
includ
antidepress
gprotein
antipsychot
dopamin
serotonin
sulfonylurea
sulfonylurea
receptor
protein
anesthet
ryanodin
receptor
johnson
addit
similar
associ
studi
drug
toxic
diseas
polymorph
includ
abacavir
major
histocompat
protein
risk
hypersensit
cisaprid
terfenadin
herg
mink
increas
risk
druginduc
torsad
de
point
oral
contracept
prothrombin
factor
v
increas
deep
vein
thrombosi
johnson
likewis
similar
associ
efficaci
known
statin
apolipoprotein
e
enhanc
surviv
prolong
simvastatin
tacrin
apolipoprotein
e
clinic
improv
alzheim
symptom
johnson
due
intim
role
genet
carcinogenesi
person
medicin
rapidli
becom
success
stori
oncolog
base
genet
profi
ling
use
proteom
analys
tumor
biopsi
garnett
kelloff
sigman
shaw
johnson
describ
target
cancer
therapi
trastuzumab
herceptin
success
view
way
futur
also
clinic
import
polymorph
predict
increas
toxic
patient
cancer
treat
chemotherapeut
drug
exampl
thiopurin
methyltransferas
variant
uorouracil
dihydropyrimidin
dehydrogenas
variant
irinotecan
allel
fdaapprov
invad
molecular
assay
diagnost
avail
screen
presenc
allel
associ
irinotecan
toxic
kolesar
likewis
clinic
import
pharmacogenet
predict
effi
caci
oncolog
patient
treat
thymidyl
synthas
variant
petro
sharma
classic
applic
pharmacogenet
present
understand
potenti
fatal
hematopoiet
toxic
occur
patient
administ
standard
dose
antileukem
agent
azathioprin
mercaptopurin
thioguanin
zhou
petro
sharma
drug
metabol
enzym
thiopurin
methyltransferas
tpmt
inact
smethyl
product
gene
mutat
polymorph
may
occur
mani
patient
result
decreas
tpmtmediat
metabol
thiopurin
drug
diagnost
test
tpmt
avail
use
clinic
identifi
ed
patient
poor
tpmt
metabol
may
need
drug
dose
lower
mechan
multidrug
resist
cancer
drug
infl
uenc
genet
differ
number
polymorph
gene
code
pglycoprotein
transmembran
protein
drug
effl
ux
pump
respons
multidrug
resist
identifi
ed
one
known
tt
genotyp
correl
decreas
intestin
express
pglycoprotein
increas
drug
bioavail
allel
frequenc
africanamerican
popul
yet
approxi
mate
caucasianamerican
popul
kolesar
pharmacogenet
pharmacogenom
analysi
patient
activ
studi
mani
diseas
state
howev
detail
discuss
goe
beyond
introduct
may
provid
reader
encourag
read
pharmacogenet
pharmacogenomicrel
refer
end
chapter
exampl
includ
infecti
diseas
genet
predisposit
infect
host
roger
cardiovascular
diseas
gene
link
heart
failur
treat
hypertens
warfarin
anticoagul
therapi
lipid
lower
drug
zineh
pacanowski
psychiatri
role
drug
metabol
receptor
express
drug
respons
rate
antidepress
antipsychot
drug
weight
gain
antipsychot
ellingrod
et
al
asthma
leukotrien
inhibitor
betaagonist
blake
et
al
transplant
cyclosporin
metabol
multidrug
resist
effl
ux
mechan
burckert
mani
key
success
person
medicin
hing
continu
scientifi
c
advanc
great
advanc
genom
scienc
question
good
patient
stage
develop
due
exagger
claim
fall
short
predict
prevent
healthcar
paradigm
promis
browman
et
al
natur
biotechnolog
editori
staff
pace
advanc
slower
promis
zuckerman
miln
also
econom
societ
ethic
issu
must
address
success
implement
genet
testingbas
individu
pharmacotherapi
huston
fair
state
drug
effect
patient
time
thu
pressur
payer
move
payment
product
payment
clinic
signifi
cant
health
outcom
model
reason
use
omic
health
technolog
health
informat
approach
stratifi
patient
popul
drug
effect
drug
safeti
laudabl
goal
howev
technolog
current
quit
expens
result
drug
respons
predict
valid
clinic
costeffect
costbenefi
analys
limit
date
chalkid
rawlin
also
result
environ
creat
technolog
context
outcom
expect
new
drug
accessreimburs
model
give
rise
new
pharmaceut
busi
paradigm
still
evolv
well
understood
fda
approv
refer
fi
rst
racial
target
drug
bidil
isosorbid
hydralazin
nitrom
branca
omic
technolog
gener
involv
develop
approv
process
base
analysi
health
statist
suggest
rate
mortal
black
heart
diseas
twice
high
white
age
group
clinic
trial
older
drug
combin
africanamerican
conduct
improv
surviv
treatment
arm
result
fda
approv
drug
exclus
africanamerican
yet
modern
anthropolog
genet
shown
race
exist
real
social
construct
genet
distinguish
human
racial
group
ossorio
thu
attribut
observ
differ
biomed
outcom
phenotyp
observ
genet
differ
among
race
problemat
ethic
challeng
race
like
surrog
marker
environment
genet
caus
diseas
respons
pharmacotherapi
factor
introduct
omic
technolog
broadli
healthcar
manner
segreg
patient
popul
base
genom
proteom
characterist
obviou
modern
technolog
pose
provoc
consequ
public
polici
includ
data
protect
insur
access
care
challeng
must
address
decis
maker
scientist
healthcar
provid
public
person
medicin
success
insight
complex
area
pleas
read
brazeau
brazeau
conclus
even
challeng
question
progress
person
medicin
global
concern
unpreced
opportun
scienc
clinic
succeed
dna
herit
biomolecul
contain
genet
inform
result
phenotyp
parent
offspr
modern
genom
gwa
snp
analys
confi
rm
identifi
genet
variant
may
associ
differ
phenotyp
howev
genomelevel
inform
alon
gener
predict
phenotyp
individu
level
daxing
whitelaw
instanc
research
clinician
known
time
individu
respons
drug
affect
genet
makeup
dna
sequenc
genotyp
set
diseas
environment
characterist
work
alon
concert
determin
respons
research
anim
model
suggest
addit
dna
sequenc
number
level
inform
infl
uenc
transcript
genom
inform
awar
everi
person
bodi
contain
trillion
cell
essenti
genom
therefor
gene
yet
cell
optim
develop
one
special
cell
make
bodi
muscl
bone
brain
etc
transpir
within
genom
gene
must
turn
differ
point
cell
develop
differ
cell
type
affect
gene
express
protein
product
cell
differenti
growth
function
rapidli
evolv
fi
eld
research
known
epigenet
epigenom
view
conduit
genotyp
phenotyp
epigenet
liter
mean
genet
genet
sequenc
factor
factor
infl
uenc
cell
behavior
mean
via
direct
effect
genet
machineri
epigenet
regul
includ
dna
methyl
coval
histon
modifi
cation
fig
mitot
andor
meiotic
herit
chang
gene
express
result
without
chang
dna
sequenc
berger
et
al
epigenom
merg
scienc
genom
epigenet
raghavachari
function
epigenet
act
regul
gene
express
gene
silenc
genom
imprint
apoptosi
xchromosom
inactiv
tissuespecifi
c
gene
activ
mainten
stem
cell
pluripot
garsk
denu
understand
epigenet
epigenom
like
understand
phenotyp
trait
result
genet
inform
alon
epigeneticsepigenom
may
also
explain
low
associ
predictor
found
pharmacogeneticpharmacogenom
studi
etiolog
diseas
cancer
like
involv
genet
variant
epigenet
modifi
cation
could
result
environment
effect
bjornsson
et
al
jirtl
skinner
age
also
like
infl
uenc
epigenet
modifi
cation
studi
ident
twin
show
greater
differ
global
dna
methyl
older
rather
younger
set
twin
feinberg
et
al
abnorm
epigenet
regul
like
featur
complex
diseas
diabet
cancer
heart
diseas
chen
zhang
hamm
costa
rakyan
et
al
therefor
epigenet
target
explor
drug
design
especi
observ
cancer
woster
fi
rst
gener
fdaapprov
epigeneticsbas
drug
avail
two
dna
demethyl
agent
decitabin
two
histon
deacetylas
hdac
inhibitor
vorinostat
romidepsin
approv
mainli
treatment
blood
cancer
particularli
myelodysplast
syndrom
md
one
studi
best
understood
molecular
mechan
epigenet
regul
methyl
cytosin
residu
specifi
c
posit
dna
molecul
fig
portela
estel
anoth
mechan
epigenom
control
appear
occur
level
chromatin
cell
dna
wrap
around
differ
histon
protein
form
chromatin
packag
dna
chromatin
render
larg
region
dna
inaccess
prevent
process
dna
transcript
occur
epigenet
regul
histon
protein
chemic
modifi
cation
includ
acetyl
methyl
sumoyl
ubiquityl
herceg
murr
caus
structur
chang
chromatin
affect
dna
access
nonproteincod
rna
known
ncrna
also
shown
contribut
epigenet
regul
mrna
process
particip
variou
interfer
pathway
collin
schonfeld
toxicogenom
relat
pharmacogenom
combin
toxicolog
genet
molecular
biolog
environment
health
elucid
respons
live
organ
stress
environ
xenobiot
agent
base
upon
genet
makeup
rockett
toxicogenom
studi
genom
histon
tail
histon
chromoson
dna
dna
methyl
group
respond
toxic
exposur
pharmacogenet
studi
individu
genet
makeup
affect
hisher
respons
environment
stress
toxin
carcinogen
neurotoxin
reproduct
toxin
smith
toxicogenom
use
drug
discoveri
develop
new
drug
candid
screen
combin
gene
express
profi
ling
toxicolog
understand
gene
respons
identifi
gener
mechan
toxic
possibl
predict
drug
safeti
fur
blomm
suggest
toxicogenom
may
decreas
time
need
toxicolog
investig
new
drug
candid
reduc
cost
anim
usag
versu
convent
toxic
studi
genom
techniqu
util
toxicogenom
studi
includ
gene
express
level
profi
ling
snp
analysi
genet
variat
proteom
andor
metabolom
method
gene
express
protein
product
metabolit
product
may
studi
raghavachari
rapid
growth
nextgener
dna
sequenc
capabl
may
drive
convers
microarray
commonli
use
snp
analysi
ng
technolog
toxicogenom
studi
attempt
discov
associ
develop
drug
toxic
genotyp
clinician
research
attempt
correl
genet
variat
one
popul
manifest
toxic
popul
identifi
predict
advers
toxicolog
effect
clinic
trial
suitabl
biomark
advers
effect
develop
use
method
would
theoret
possibl
test
individu
patient
suscept
advers
effect
prescrib
medic
patient
would
show
marker
advers
effect
would
switch
differ
drug
therefor
toxicogenom
becom
increasingli
power
predict
toxic
new
biomark
identifi
ed
valid
first
describ
fi
eld
infanc
yet
emerg
rapidli
much
new
toxicogenom
technolog
develop
pharmaceut
industri
corpor
laboratori
novel
scientifi
c
fi
eld
glycom
glycobiolog
may
defi
ned
simpli
studi
structur
synthesi
biolog
function
glycan
may
refer
oligosaccharid
polysaccharid
depend
size
glycoconjug
simpl
complex
system
varkin
et
al
fukuda
hindsgaul
raghavachari
applic
glycom
glycobiolog
sometim
call
glycotechnolog
distinguish
biotechnolog
refer
glycan
rather
protein
nucleic
acid
howev
mani
biotech
arena
consid
glycobiolog
one
research
fi
eld
encompass
term
biotechnolog
postgenom
era
intricaci
protein
glycosyl
mechan
genet
control
intern
extern
factor
infl
uenc
extent
pattern
glycosyl
import
understand
protein
function
proteom
like
protein
nucleic
acid
glycan
biopolym
refer
last
frontier
pharmaceut
discoveri
recent
advanc
biotechnolog
discov
clone
har
sugar
cleav
synthes
enzym
enabl
glycobiologist
analyz
manipul
complex
carbohydr
easili
walsh
jefferi
mani
protein
produc
anim
cell
contain
attach
sugar
moieti
make
glycoprotein
major
proteinbas
medicin
agent
contain
form
posttransl
modif
profoundli
affect
biolog
activ
protein
bacteri
host
recombin
dna
could
produc
anim
protein
ident
nearli
ident
amino
acid
sequenc
howev
earli
work
bacteria
lack
abil
attach
sugar
moieti
protein
process
call
glycosyl
new
methodolog
may
help
overcom
issu
cf
chap
mani
nonglycosyl
protein
differ
biolog
activ
compar
nativ
glycoprotein
product
anim
protein
lack
glycosyl
provid
unexpect
opportun
studi
function
role
sugar
molecul
glycoprotein
extens
progress
glycoengin
yeast
human
nglycosyl
pathway
result
therapeut
glycoprotein
express
yeast
wildt
gerngross
complex
fi
eld
best
illustr
review
build
block
glycan
simpl
carbohydr
call
saccharid
sugar
deriv
ie
amino
sugar
simpl
carbohydr
attach
type
biolog
molecul
form
glycoconjug
includ
glycoprotein
predominantli
protein
glycolipid
proteoglycan
polysaccharid
protein
carbohydr
chemistri
biolog
activ
area
research
centuri
advanc
biotechnolog
provid
techniqu
ad
energi
studi
glycan
oligosaccharid
found
conjug
protein
glycoprotein
lipid
glycolipid
display
tremend
structur
divers
linkag
monomer
unit
protein
nucleic
acid
gener
consist
molecul
glycan
howev
exhibit
far
greater
variabl
linkag
monomer
unit
found
biopolym
exampl
fig
illustr
common
linkag
site
creat
polym
glucos
glucos
link
four
posit
also
take
one
two
possibl
anomer
confi
gurat
effect
multipl
linkag
arrang
seen
estim
kobata
estim
oligom
length
number
structur
distinct
linear
oligom
biopolym
dna
possibl
base
protein
possibl
amino
acid
oligosaccharid
eight
monosaccharid
type
pattern
glycosyl
signifi
cantli
affect
biolog
activ
protein
wildt
gerngross
walsh
jefferi
mani
therapeut
use
recombin
dnaproduc
protein
glycosyl
includ
erythropoietin
glucocerebrosidas
tissu
plasminogen
activ
without
appropri
carbohydr
attach
none
protein
function
therapeut
parent
glycoprotein
glycoform
variat
glycosyl
pattern
glycoprotein
protein
may
differ
physicochem
biochem
properti
exampl
erythropoietin
one
olink
three
nlink
glycosyl
site
remov
termin
sugar
site
destroy
vivo
activ
remov
sugar
result
rapid
clearanc
molecul
shorter
circulatori
halflif
takeuchi
et
al
yet
opposit
effect
observ
deglycosyl
hematopoiet
cytokin
granulocytemacrophag
colonystimul
factor
gmcsf
cebon
et
al
case
remov
carbohydr
residu
increas
specifi
c
activ
sixfold
sugar
glycoprotein
known
play
role
recognit
bind
biomolecul
molecul
diseas
state
asthma
rheumatoid
arthriti
cancer
hiv
infect
fl
u
infecti
diseas
lipid
fundament
compon
membran
play
multifacet
role
cell
tissu
organ
physiolog
rel
new
research
area
lipidom
may
defi
ned
largescal
studi
pathway
network
cellular
lipid
biolog
system
wenk
raghavachari
metabolom
would
includ
major
class
biolog
molecul
protein
amino
acid
nucleic
acid
carbohydr
lipidom
would
subset
metabolom
describ
complet
lipid
profi
le
within
cell
tissu
whole
organ
lipidom
research
vast
amount
inform
structur
function
interact
dynam
quantit
describ
alter
content
composit
differ
lipid
molecular
speci
accru
perturb
cell
tissu
organ
chang
physiolog
patholog
state
studi
lipidom
import
better
understand
mani
metabol
diseas
lipid
believ
play
role
obes
atherosclerosi
stroke
hypertens
diabet
lipid
profi
ling
target
metabolom
platform
provid
comprehens
analysi
lipid
speci
within
cell
possibl
tissu
progress
modern
lipidom
greatli
acceler
develop
sensit
analyt
techniqu
electrospray
ioniz
esi
matrixassist
laser
desorptionion
maldi
current
isol
subsequ
analysi
lipid
mixtur
hamper
extract
analyt
limit
due
characterist
lipid
chemistri
welldevelop
tool
techniqu
genom
bioinformat
appli
examin
intric
interplay
mammalian
diet
genet
makeup
nutrigenom
nutrit
genom
defi
ned
infl
uenc
genet
variat
nutrit
appear
result
gene
express
andor
gene
variat
eg
snp
analysi
nutrient
absorpt
distribut
metabol
elimin
biolog
effect
laursen
includ
nutrient
impact
product
action
specifi
c
gene
product
express
protein
turn
affect
respons
nutrient
nutrigenom
studi
aim
develop
predict
mean
optim
nutrit
respect
individu
genotyp
area
studi
includ
dietari
supplement
common
food
beverag
mother
milk
well
diseas
cardiovascular
obes
diabet
still
infanc
nutrigenom
thought
critic
scienc
person
health
public
health
next
decad
kaput
et
al
pharmaceut
scientist
pharmacist
may
hear
omic
technolog
omic
term
deriv
applic
modern
genom
techniqu
studi
variou
biolog
properti
process
exampl
interactom
dataintens
broad
system
studi
interactom
interact
among
protein
molecul
within
cell
proteogenom
use
broadli
encompass
term
describ
merg
genom
proteom
small
molecul
informat
cellom
defi
ned
studi
gene
function
protein
encod
live
cell
util
light
microscopi
especi
digit
imag
fl
uoresc
microscopi
human
genom
project
develop
bioinformat
technolog
catalyz
fundament
chang
practic
modern
biolog
help
unveil
remark
amount
inform
mani
organ
aderem
hood
price
et
al
biolog
becom
inform
scienc
defi
ning
element
complex
biolog
system
place
databas
compar
interpret
seen
fig
hierarchi
inform
collect
goe
well
beyond
biodata
contain
genet
code
transcrib
translat
system
biolog
involv
gener
complex
interact
system
research
area
often
describ
noncompetit
precompetit
technolog
pharmaceut
industri
believ
foundat
technolog
must
better
develop
success
competit
technolog
drug
discoveri
develop
studi
interact
compon
biolog
system
interact
give
rise
function
behavior
system
system
biolog
essenti
understand
individu
part
intric
biolog
network
organ
function
live
cell
biolog
system
may
involv
enzym
metabolit
metabol
pathway
interact
biolog
molecul
affect
biolog
process
molecular
biologist
spent
past
year
teas
apart
cellular
pathway
molecular
level
character
cycl
theori
comput
model
experi
quantit
describ
cell
cell
process
system
biolog
dataintens
endeavor
result
conceptu
framework
analysi
understand
complex
biolog
system
vari
context
rothberg
et
al
klipp
et
al
meyer
et
al
statist
mine
data
align
probabilist
mathemat
model
data
visual
network
among
mathemat
model
employ
integr
data
assembl
system
network
gehlenborg
et
al
new
measur
store
exist
data
includ
extens
function
annot
molecular
databas
model
assembl
provid
librari
network
model
schrattenholz
et
al
biolog
interact
network
extrem
complex
graphic
represent
network
year
research
set
guidelin
known
system
biolog
graphic
notat
sbgn
gener
accept
standard
graphic
represent
research
standard
design
facilit
interchang
system
biolog
inform
storag
due
complex
diagram
depend
interact
examin
level
understand
fi
gure
relat
system
biolog
includ
chapter
howev
reader
refer
follow
websit
author
sbgn
organ
sever
excel
exampl
complex
system
biologyderiv
protein
interact
network
http
www
inabl
visual
complex
biolog
system
past
imped
identifi
cation
valid
new
novel
drug
target
accept
sbgn
standard
facilit
effort
pharmaceut
scientist
valid
new
novel
target
drug
design
hood
perlmutt
sinc
object
model
interact
system
experiment
techniqu
suit
system
biolog
systemwid
attempt
complet
possibl
highthroughput
omic
technolog
genom
epigenom
proteom
pharmacogenom
transcriptom
metabolom
toxicogenom
use
collect
quantit
data
construct
valid
system
model
pharmaceut
clinic
end
point
includ
system
level
biomark
genet
risk
factor
aspect
person
medicin
drug
target
identifi
cation
price
et
al
yuryev
futur
applic
system
biolog
approach
drug
discoveri
promis
profound
impact
patientcent
medic
practic
permit
comprehens
evalu
underli
predisposit
diseas
diseas
diagnosi
diseas
progress
also
realiz
person
medicin
system
medicin
requir
new
analyt
approach
system
biolog
deciph
extraordinarili
larg
extraordinarili
noisi
data
set
price
et
al
thousand
year
man
select
bred
anim
plant
either
enhanc
creat
desir
trait
numer
speci
explos
develop
recombin
dna
technolog
molecular
biolog
techniqu
made
possibl
engin
speci
possess
particular
uniqu
distinguish
genet
characterist
describ
chap
genet
materi
anim
plant
manipul
extra
gene
may
insert
transgen
replac
ie
human
gene
homolog
code
relat
human
protein
delet
knockout
theoret
approach
enabl
introduct
virtual
gene
organ
greater
understand
specifi
c
gene
regul
express
contribut
import
new
discoveri
made
relev
anim
model
genet
alter
speci
found
util
myriad
research
potenti
commerci
applic
includ
gener
model
human
diseas
protein
drug
product
creation
organ
tissu
xenotransplant
host
agricultur
use
drug
discoveri
dunn
et
al
clark
pazdernik
b
describ
chap
term
transgen
anim
describ
anim
foreign
dna
segment
transgen
incorpor
genom
later
term
extend
also
includ
anim
endogen
genom
dna
molecular
structur
manipul
similar
transgen
technolog
gene
therapi
import
distinguish
clearli
technic
speak
introduct
foreign
dna
sequenc
live
cell
call
gene
transfer
thu
one
method
creat
transgen
anim
involv
gene
transfer
transgen
incorpor
genom
gene
therapi
cf
chap
also
gene
transfer
procedur
sens
produc
transgen
human
transgen
anim
howev
foreign
gene
transfer
indiscrimin
cell
includ
germ
line
cell
process
gene
therapi
differ
gener
transgenesi
sinc
involv
transfer
desir
gene
way
involv
specifi
c
somat
hematopoiet
cell
germ
cell
thu
unlik
gene
therapi
genet
chang
transgen
organ
conserv
offspr
accord
gener
rule
mendelian
inherit
product
transgen
anim
new
technolog
dunn
et
al
clark
pazdernik
khan
produc
sinc
howev
modern
biotechnolog
greatli
improv
method
induc
genet
transform
mous
studi
anim
speci
transgen
technolog
appli
cattl
fi
sh
especi
zebra
fi
sh
goat
poultri
rabbit
rat
sheep
swine
cat
dog
hors
mule
deer
variou
lower
anim
form
mosquito
tabl
transgen
anim
alreadi
made
valuabl
research
contribut
studi
involv
regul
gene
express
function
immun
system
genet
diseas
viral
diseas
cardiovascular
diseas
gene
respons
develop
cancer
transgen
anim
proven
indispens
drug
lead
identifi
cation
lead
optim
preclin
drug
develop
diseas
model
product
transgen
anim
commonli
involv
microinject
also
call
gene
transfer
copi
exogen
transgen
dna
larger
visibl
male
pronucleu
compar
femal
pronucleu
recipi
fertil
embryo
see
fig
clark
pazdernik
khan
transgen
contain
dna
encod
desir
target
amino
acid
sequenc
along
regulatori
sequenc
mediat
express
ad
gene
microinject
egg
implant
reproduct
tract
femal
allow
develop
embryo
foreign
dna
gener
becom
randomli
insert
singl
site
one
host
chromosom
ie
founder
transgen
anim
heterozyg
thu
transgen
founder
anim
posit
transgen
incorpor
anim
uniqu
speci
interbreed
founder
transgen
anim
transgen
incorpor
germ
cell
may
result
birth
homozyg
progeni
provid
transgen
incorpor
induc
mutat
essenti
endogen
gene
cell
transgen
anim
contain
transgen
dna
insert
occur
prior
fi
rst
cell
divis
howev
usual
offspr
contain
detect
level
transgen
select
neonat
anim
possess
incorpor
transgen
readili
accomplish
either
direct
identifi
cation
specifi
c
dna
mrna
sequenc
observ
gross
phenotyp
characterist
product
fi
rst
genet
alter
laboratori
mous
embryo
insert
transgen
via
modifi
ed
retrovir
vector
clark
pazdernik
khan
see
chap
detail
descript
retrovir
vector
gene
therapi
nonrepl
viral
vector
bind
embryon
host
cell
allow
subsequ
transfer
insert
transgen
host
genom
mani
experiment
human
gene
therapi
trial
employ
viral
vector
advantag
method
transgen
product
eas
gene
introduc
embryo
variou
stage
develop
characterist
singl
copi
transgen
usual
integr
genom
disadvantag
includ
possibl
genet
recombin
viral
vector
virus
present
size
limit
introduc
dna
kb
dna
less
size
gene
diffi
culti
prepar
certain
viral
vector
transgen
anim
also
produc
vitro
genet
alter
pluripot
embryon
stem
cell
es
cell
see
fig
cf
chap
clark
pazdernik
khan
es
cell
technolog
effi
cient
creat
transgen
microinject
protocol
es
cell
cultur
cell
line
deriv
inner
cell
mass
blastocyst
blastocyt
earli
preimplant
embryo
capabl
genom
dna
modifi
ed
retain
abil
contribut
somat
germ
cell
lineag
desir
gene
incorpor
es
cell
one
sever
method
microinject
follow
introduct
genet
modifi
ed
es
cell
blastocyst
earli
preimplant
embryo
select
cultur
target
es
cell
transfer
subsequ
reproduct
tract
surrog
host
anim
result
progeni
screen
evid
desir
genet
modifi
cation
present
select
appropri
mice
process
result
approxim
progeni
contain
tissu
genet
deriv
incorpor
es
cell
interbreed
select
founder
anim
produc
speci
homozyg
mutat
transform
embryon
stem
cell
effi
cient
microinject
techniqu
describ
fi
rst
desir
gene
must
still
insert
cultur
stem
cell
genom
ultim
produc
transgen
anim
gene
insert
could
occur
random
target
process
nonhomolog
recombin
random
process
readili
occur
desir
dna
introduc
es
cell
genom
gene
recombin
process
requir
sequenc
homolog
genom
dna
foreign
dna
es
cell
fail
insert
foreign
dna
select
inject
inner
cell
mass
anim
blastocyst
thu
eventu
lead
transgen
speci
still
far
fewer
es
cell
homolog
recombin
occur
chanc
segment
dna
base
sequenc
vector
fi
nd
homolog
sequenc
host
genom
region
homolog
sequenc
replac
match
region
host
dna
signifi
cant
advanc
product
transgen
anim
es
cell
advent
target
homolog
recombin
techniqu
homolog
recombin
much
rare
point
transgen
research
nonhomolog
recombin
favor
research
care
design
engin
transfer
dna
specifi
c
sequenc
homolog
endogen
dna
desir
integr
site
also
care
select
transfer
vector
condit
target
homolog
recombin
precis
chromosom
posit
provid
approach
subtl
genet
modifi
cation
anim
use
produc
knockout
mice
discuss
later
modifi
cation
procedur
involv
use
hematopoiet
bone
marrow
stem
cell
rather
pluripot
embryon
stem
cell
use
es
cell
result
chang
whole
germ
line
hematopoiet
stem
cell
modifi
ed
appropri
expect
repopul
specifi
c
somat
cell
line
line
similar
gene
therapi
scienc
clone
result
ethic
debat
surround
well
beyond
scope
chapter
yet
import
place
concept
anim
clone
within
pharmaceut
import
context
transgen
anim
product
techniqu
microinject
variat
form
basi
commerci
transgen
anim
product
success
microinject
process
limit
creation
small
number
transgen
anim
given
birth
slow
process
convent
breed
result
transgen
progeni
must
follow
produc
larger
number
transgen
anim
transgen
origin
organ
gener
herd
fl
ock
etc
altern
approach
would
advantag
techniqu
nuclear
transfer
replac
nuclear
genom
dna
oocyt
immatur
egg
singlecel
fertil
embryo
donor
cell
altern
breed
methodolog
anim
clone
result
nuclear
transfer
technolog
judg
journal
scienc
import
breakthrough
creat
sheep
dolli
fi
rst
clone
mammal
singl
cell
old
ewe
feat
mani
thought
imposs
dolli
born
nuclear
transfer
genom
adult
mammari
gland
cell
khan
sinc
announc
commerci
exploratori
develop
nuclear
transfer
technolog
progress
rapidli
variou
speci
clone
import
note
clone
sheep
dolli
transgen
anim
dolli
clone
adult
ewe
possess
transgen
howev
clone
could
use
breed
clone
transgen
anim
directli
produc
transgen
anim
prior
nuclear
transfer
transgen
insert
genom
clone
donor
exampl
human
factor
ix
blood
factor
protein
transgen
sheep
gener
nuclear
transfer
transfect
fetal
fi
broblast
schnieck
et
al
sever
result
progeni
shown
transgen
ie
possess
human
factor
ix
gene
one
name
polli
thu
anim
clone
util
breed
also
product
potenti
human
therapeut
protein
use
pharmaceut
product
shultz
et
al
varieti
biotechnolog
genet
engin
techniqu
employ
creat
wealth
transgen
plant
speci
mention
chap
cotton
maiz
soybean
potato
petunia
tobacco
papaya
rose
other
clark
pazdernik
khan
agricultur
enhanc
result
engin
plant
herbicid
toler
insect
resist
fungu
resist
viru
resist
stress
toler
baez
import
human
health
pharmaceut
biotechnolog
gene
transfer
technolog
routin
use
manipul
bulk
human
protein
product
wide
varieti
transgen
plant
speci
signifi
cant
note
transgen
plant
attract
bulk
bioreactor
posttransl
modif
process
often
result
plantderiv
recombin
human
protein
greater
glycosyl
pattern
similar
found
correspond
nativ
human
protein
would
observ
correspond
mammalian
product
system
transgen
seed
would
result
seedl
capabl
express
human
protein
transplant
fi
eld
follow
normal
growth
harvest
biomass
downstream
isol
protein
purifi
cation
result
valuabl
altern
crop
farm
tobacco
fi
eld
produc
pharmaceut
grade
human
antibodi
sometim
refer
plantibodi
edibl
vaccin
contain
transgen
potato
tomato
futurist
vision
current
research
project
academ
corpor
laboratori
farmer
fi
eld
sole
site
human
protein
product
fl
ora
exampl
cultur
eukaryot
microalga
also
develop
use
express
system
especi
human
human
antibodi
mayfi
eld
franklin
antibodybas
target
therapeut
becom
increasingli
import
use
transgen
plant
like
continu
expand
research
help
solv
problem
relat
isol
activ
protein
drug
issu
concern
cross
fertil
nongenet
modifi
ed
organ
nongmo
use
transgen
anim
plant
bioreactor
product
pharmaceut
import
protein
may
becom
one
import
use
engin
speci
numer
practic
challeng
address
baez
klimyuk
et
al
tabl
provid
list
select
exampl
biopharmaceut
transgen
anim
plant
util
convent
agronom
farm
techniqu
transgen
anim
plant
offer
opportun
produc
practic
unlimit
quantiti
biopharmaceut
techniqu
produc
transgen
anim
use
develop
anim
strain
secret
high
level
import
protein
variou
end
organ
milk
blood
urin
tissu
larg
anim
gene
farm
transgen
anim
serv
bioreactor
synthes
recover
quantiti
therapeut
use
protein
among
advantag
express
protein
anim
milk
protein
gener
produc
sizabl
quantiti
harvest
manual
mechan
simpli
milk
anim
protein
purifi
cation
milk
requir
usual
separ
techniqu
protein
gener
recombin
gene
code
desir
protein
product
fuse
regulatori
sequenc
anim
milkproduc
gene
anim
endang
insert
recombin
gene
logic
fusion
protein
product
gene
milkproduc
gene
target
transcript
translat
protein
product
exclus
mammari
tissu
normal
involv
milk
product
permit
gene
activ
nonmilkproduc
tissu
anim
protein
product
potenti
indic
data
refer
note
section
chap
abbrevi
tpa
tissu
plasminogen
activ
latpa
long
act
tissu
plasminogen
activ
tissu
growth
factorbeta
tabl
exampl
human
protein
develop
transgen
anim
plant
genom
omic
technolog
transgen
strain
establish
perpetu
breed
anim
sinc
progeni
origin
transgen
anim
founder
anim
usual
also
produc
desir
recombin
protein
yield
protein
pharmaceut
produc
transgen
expect
time
greater
achiev
recombin
cell
cultur
protein
yield
transgen
anim
gener
good
conserv
estim
gl
gl
purifi
cation
effi
cienci
milk
yield
variou
speci
per
annum
estim
cow
l
sheep
l
goat
l
pig
l
rudolph
ppl
therapeut
estim
cost
produc
human
therapeut
protein
larg
anim
bioreactor
could
much
less
expens
cell
cultur
addit
desir
target
protein
requir
posttransl
modifi
cation
larg
mammal
use
milk
product
pharmaceut
would
bioreactor
capabl
ad
group
unlik
recombin
bacteri
cultur
exampl
human
long
peptid
protein
develop
milk
transgen
anim
includ
growth
hormon
calcitonin
insulinlik
growth
factor
alpha
antitrypsin
clot
factor
viii
clot
factor
ix
tissu
plasminogen
activ
tpa
lactoferrin
gastric
lipas
vaccin
deriv
escherichia
coli
ltb
toxin
subunit
protein
c
variou
human
monoclon
antibodi
xenomous
garner
colman
rudolph
fi
rst
approv
biopharmaceut
transgen
anim
recombin
human
antithrombin
remain
market
today
trade
name
atryn
produc
herd
transgen
dairi
goat
rhat
express
high
level
milk
human
transgen
assembl
link
cdna
normal
milk
protein
sequenc
xhoi
site
goat
beta
casein
vector
see
tabl
addit
exampl
use
genet
engin
techniqu
creat
transgen
plant
pharm
pharmaceut
produc
everexpand
list
drug
diagnost
agent
deriv
human
gene
baez
opar
exampl
human
peptid
protein
develop
transgen
plant
includ
tgfbeta
vitronectin
thyroidstimul
hormon
receptor
insulin
glucocerebrosidas
apolipoprotein
taligluceras
alfa
see
tabl
addit
exampl
innov
use
transgen
product
use
protein
gener
clinic
transplant
transgen
anim
organ
controversi
crossspeci
transplant
khan
success
humantohuman
transplant
heart
kidney
liver
vascular
organ
allotransplant
creat
signifi
cant
expect
need
donor
organ
primatetohuman
transplant
xenotransplant
success
ethic
issu
limit
number
donor
anim
signifi
cant
barrier
transplant
surgeon
recogn
earli
organ
pig
ration
choic
xenotransplant
due
physiolog
anatom
ethic
suppli
reason
seriou
hyperacut
reject
could
overcom
sever
research
group
academia
industri
pioneer
transgen
engin
pig
express
human
complement
inhibitori
protein
key
human
blood
group
protein
antigen
mccurri
et
al
dunn
et
al
van
eyck
et
al
clone
produc
transgen
pig
xenotransplant
cell
tissu
organ
doubl
transgen
anim
appear
resist
humor
immun
systemmedi
reaction
primat
like
human
fi
nding
begin
pave
way
potenti
xenograft
transplant
anim
compon
human
lessen
chanc
acut
reject
continu
concern
mani
anim
pig
shorter
life
span
human
mean
tissu
age
quicker
rate
mani
speci
includ
mice
zebra
fi
sh
nematod
transform
lose
genet
function
studi
drug
discoveri
diseas
model
mice
proven
use
mice
laboratori
anim
speci
close
relat
human
knockout
techniqu
easili
perform
favorit
subject
knockout
experi
mous
carri
introduc
transgen
call
transgen
mous
transgen
technolog
also
produc
knockout
anim
knockout
mous
also
call
gene
knockout
mous
genetarget
knockout
mous
anim
endogen
gene
genom
wildtyp
allel
specifi
calli
inactiv
replac
null
allel
sharpless
depinho
wu
et
al
clark
pazdernik
null
allel
nonfunct
allel
gene
gener
either
delet
entir
gene
mutat
gene
result
synthesi
inact
protein
recent
advanc
intranuclear
gene
target
embryon
stem
cell
technolog
describ
expand
capabl
produc
knockout
mice
routin
studi
certain
human
genet
diseas
elucid
function
specifi
c
gene
product
procedur
produc
knockout
mice
basic
involv
fourstep
process
null
allel
ie
knockout
allel
incorpor
one
allel
murin
es
cell
incorpor
gener
quit
low
approxim
one
cell
million
requir
gene
replac
howev
process
design
impart
neomycin
ganciclovir
resist
es
cell
homolog
gene
integr
result
facilit
select
propag
correctli
engin
es
cell
result
es
cell
inject
earli
mous
embryo
creat
chimer
mice
heterozyg
knockout
allel
contain
tissu
deriv
host
cell
es
cell
chimer
mice
mate
confi
rm
null
allel
incorpor
germ
line
confi
rmed
heterozyg
chimer
mice
bred
homogen
produc
progeni
homozyg
knockout
mice
worldwid
three
major
mous
knockout
program
proceed
collabor
creat
mutat
approxim
proteincod
gene
mous
genom
use
combin
gene
trap
gene
target
mous
embryon
stem
es
cell
staff
includ
continu
discoveri
three
worldwid
mous
knockout
consortia
independ
research
laboratori
around
world
creat
better
model
human
monogen
polygen
diseas
cancer
diabet
obes
cardiovascular
diseas
psychiatr
neurodegen
diseas
exampl
knockout
mice
engin
extrem
elev
cholesterol
level
maintain
normal
chow
diet
due
inabl
produc
apolipoprotein
e
apoprotein
e
apoprotein
e
major
lipoprotein
compon
lowdens
lipoprotein
vldl
respons
liver
clearanc
vldl
engin
mice
examin
anim
model
atherosclerosi
use
cardiovascular
drug
discoveri
develop
tabl
provid
list
addit
select
exampl
knockout
mous
diseas
model
knockout
mous
becom
basic
tool
research
determin
gene
function
vivo
numer
biolog
system
exampl
knockout
mous
technolog
help
transform
understand
immun
respons
studi
singl
multipl
gene
knockout
anim
provid
new
perspect
tcell
develop
costimul
activ
human
mice
transgen
sever
combin
immunodefi
cienci
scid
mice
graft
human
cell
tissu
enabl
research
regen
medicin
infecti
diseas
cancer
human
hematopoiesi
addit
highthroughput
dna
sequenc
effort
posit
clone
program
novel
embryon
stem
cellbas
gene
discoveri
research
area
exploit
knockout
mous
laboratori
engin
anim
model
prove
invalu
pharmaceut
research
sinc
small
anim
model
diseas
may
creat
valid
mimic
diseas
human
patient
mous
rat
zebra
fi
sh
common
model
explor
use
genet
engin
predispos
anim
particular
diseas
scrutini
insert
human
gene
anim
initi
develop
clinic
relev
diseas
condit
human
clinic
studi
assess
effi
caci
safeti
often
reli
measur
effect
surrog
biomark
advers
event
report
valid
transgen
anim
model
human
diseas
allow
parallel
studi
possibl
predict
prior
enter
clinic
trial
also
possibl
screen
potenti
drug
candid
vivo
human
receptor
target
insert
anim
model
number
exampl
transgen
anim
model
human
diseas
use
drug
discoveri
develop
effort
grow
rapidli
sharpless
depinho
schultz
et
al
wu
et
al
clark
pazdernik
model
potenti
increas
effi
cienci
decreas
cost
drug
discoveri
develop
reduc
time
take
move
candid
medicin
agent
discoveri
clinic
trial
tabl
provid
list
select
exampl
genet
engin
anim
model
human
diseas
sitedirect
mutagenesi
also
call
sitespecifi
c
mutagenesi
oligonucleotidedirect
mutagenesi
protein
engin
techniqu
allow
specifi
c
amino
acid
residu
sitedirect
alter
mutat
creat
new
protein
entiti
johnson
reitz
mutagenesi
singl
amino
acid
posit
engin
protein
call
point
mutat
therefor
sitedirect
mutagenesi
techniqu
aid
examin
molecular
level
relationship
structur
function
interest
protein
techniqu
commonli
use
protein
engin
techniqu
result
nobel
prize
one
earli
research
fi
eld
dr
michael
smith
hutchison
et
al
figur
suggest
excel
exampl
possibl
theoret
mutat
activ
site
model
serin
proteas
enzym
could
engin
probe
mechan
action
enzym
structur
b
c
fig
repres
theoret
mutat
illustr
techniqu
craik
cowork
actual
test
role
aspart
acid
residu
serin
proteas
catalyt
triad
asp
ser
replac
asp
carboxyl
anion
side
chain
trypsin
asn
neutral
amid
side
chain
sitedirect
mutagenesi
observ
phdepend
chang
catalyt
activ
compar
wildtyp
parent
serin
proteas
see
fig
structur
craik
et
al
sitedirect
mutagenesi
studi
also
provid
invalu
insight
natur
intermolecular
interact
ligand
receptor
exampl
studi
effect
sitedirect
mutagenesi
variou
key
amino
acid
residu
bind
neurotransmitt
gproteincoupl
receptor
help
defi
ning
accur
model
alphaadrenerg
muscarin
receptor
bikker
et
al
modern
biotechnolog
tool
allow
number
way
studi
complex
biolog
system
exampl
describ
system
biolog
examin
complex
biolog
system
interact
integr
complex
network
new
develop
fi
eld
studi
known
synthet
biolog
explor
build
artifi
cial
complex
biolog
system
employ
mani
tool
experiment
techniqu
favor
system
biologist
synthet
biolog
look
strateg
redesign
andor
fabric
exist
biolog
system
design
construct
biolog
compon
system
alreadi
exist
natur
khalil
collin
synthet
genom
subset
synthet
biolog
focus
redesign
fabric
new
genet
materi
construct
raw
chemic
focu
synthet
biolog
often
way
take
part
natur
biolog
system
character
simplifi
use
compon
highli
unnatur
engin
biolog
system
synthet
biolog
studi
may
provid
detail
understand
complex
biolog
system
molecular
level
abl
design
construct
complex
system
also
one
practic
approach
understand
system
variou
condit
level
synthet
biologist
may
work
includ
organ
tissu
organ
intercellular
intracellular
biolog
pathway
molecular
level
mani
excit
applic
synthet
biolog
explor
hypothes
across
variou
fi
eld
scientifi
c
studi
includ
design
optim
biolog
pathway
natur
product
manufactur
new
drug
molecul
synthesi
biosens
ruder
et
al
engin
perspect
synthet
biolog
could
lead
design
build
engin
biolog
system
process
inform
modifi
exist
chemic
fabric
new
molecul
materi
maintain
enhanc
human
health
environ
obviou
societ
concern
synthet
biolog
experi
rais
broader
scienc
commun
engag
consider
effort
develop
guidelin
regul
address
issu
intellectu
properti
govern
ethic
societ
legal
implic
sever
bioethic
research
institut
publish
report
ethic
concern
public
percept
synthet
biolog
report
unit
state
presidenti
commiss
studi
bioethic
issu
call
enhanc
feder
oversight
emerg
technolog
research
team
j
craig
venter
institut
construct
fi
led
patent
applic
synthet
genom
novel
synthet
minim
bacterium
name
mycoplasma
laboratorium
smith
et
al
glass
et
al
team
abl
construct
artifi
cial
chromosom
gene
dna
sequenc
piec
togeth
base
upon
bacterium
mycoplasma
genitalium
origin
bacterium
fi
fth
dna
remov
abl
live
success
synthet
chromosom
place
venter
goal
make
cell
might
take
carbon
dioxid
atmospher
produc
methan
use
feedstock
fuel
chang
cowork
publish
pioneer
work
util
synthet
biolog
approach
assembl
two
heterolog
pathway
biosynthesi
plantderiv
terpenoid
natur
product
chang
terpenoid
highli
divers
class
lipophil
natur
product
histor
provid
rich
sourc
discoveri
pharmacolog
activ
small
molecul
anticanc
agent
paclitaxel
taxol
antimalari
artemisinin
unfortun
secondari
metabolit
typic
produc
low
abund
host
organ
isol
consequ
suffer
low
yield
high
consumpt
natur
resourc
key
step
develop
method
carri
cytochrom
base
oxid
chemistri
vivo
work
suggest
potenti
entir
metabol
pathway
design
silico
construct
bacteri
host
pharmaceut
scientist
taken
advantag
everi
opportun
techniqu
avail
aid
long
costli
unpredict
drug
discoveri
process
essenc
chap
overview
mani
applic
biotechnolog
relat
techniqu
use
drug
discoveri
design
lead
optim
develop
addit
recombin
dna
hybridoma
technolog
techniqu
describ
throughout
chap
chang
way
drug
research
conduct
refi
ning
process
optim
use
pharmacolog
properti
identifi
ed
novel
chemic
lead
minim
unwant
properti
promis
genom
proteom
metabolom
pharmacogenomicspharmacogenet
epigenom
toxicogenom
system
biolog
bioinformat
radic
chang
drug
discoveri
paradigm
eagerli
anticip
beeley
et
al
basu
oyeler
loge
et
al
figur
show
schemat
interact
three
key
element
essenti
modern
drug
discoveri
new
target
identifi
ed
genom
proteom
relat
technolog
valid
identifi
ed
target
rapid
sensit
bioassay
util
highthroughput
screen
method
new
molecul
creation
optim
employ
host
approach
key
element
underpin
point
bioinformat
sever
technolog
method
approach
list
fig
describ
previous
chapter
other
describ
tradit
drug
discoveri
program
reli
heavili
upon
random
screen
follow
analog
synthesi
lead
optim
via
structureact
relationship
studi
discoveri
novel
effi
caciou
safer
small
molecul
medicin
agent
appropri
druglik
characterist
increasingli
costli
complex
process
william
therefor
method
allow
reduct
time
money
extrem
valuabl
advanc
biotechnolog
contribut
greater
understand
caus
progress
diseas
identifi
ed
new
therapeut
target
form
basi
novel
drug
screen
new
technic
discoveri
fi
eld
proteom
target
discoveri
valid
system
biolog
expect
facilit
discoveri
new
agent
novel
mechan
action
diseas
previous
diffi
cult
imposs
treat
effort
decreas
cost
identifi
optim
use
qualiti
drug
lead
pharmaceut
import
target
research
develop
newer
approach
includ
highthroughput
screen
highthroughput
synthesi
method
recombin
dna
technolog
provid
abil
clone
express
isol
purifi
receptor
enzym
membranebound
protein
bind
protein
larger
quantiti
ever
instead
use
receptor
present
anim
tissu
partial
purifi
ed
enzym
screen
vitro
bioassay
util
exact
human
protein
target
applic
biotechnolog
vitro
screen
includ
improv
prepar
clone
membranebound
receptor
express
cell
line
carri
endogen
receptor
immobil
prepar
receptor
antibodi
ligandbind
protein
solubl
enzym
extracellular
cellsurfac
express
protein
receptor
case
today
biotechnolog
contribut
directli
understand
identifi
cation
andor
gener
drug
target
screen
eg
radioligand
bind
displac
clone
protein
receptor
previous
librari
synthet
compound
along
natur
product
microbi
ferment
plant
extract
marin
organ
invertebr
provid
divers
molecular
structur
screen
randomli
screen
made
direct
compound
investig
select
basi
structur
inform
receptor
natur
ligand
develop
sensit
radioligand
bind
assay
access
fulli
autom
robot
screen
techniqu
acceler
screen
process
highthroughput
screen
ht
provid
bioassay
thousand
compound
multipl
assay
time
cik
jurzak
rankov
et
al
process
autom
robot
util
multiwel
microtit
plate
microtit
plate
versatil
standard
ht
develop
nanopl
format
enhanc
robot
bring
greater
miniatur
speed
cellbas
biochem
assay
compani
conduct
bioassay
day
addit
modern
drug
discoveri
lead
optim
dna
microarray
allow
research
track
hundr
thousand
gene
enzym
inhibit
assay
radioligand
bind
assay
common
biochem
test
employ
technolog
becom
sophist
interact
natur
biochem
event
much
better
understood
approach
system
biolog
ht
whole
cell
assay
becom
commonplac
report
gene
assay
routin
util
ht
ullmann
typic
report
gene
report
indic
presenc
absenc
particular
gene
product
turn
refl
ect
chang
biolog
process
pathway
transfect
desir
cell
gene
product
express
live
cell
report
gene
transcrib
report
translat
yield
protein
measur
biochem
common
report
gene
code
enzym
luciferas
intens
result
green
fl
uoresc
protein
ie
quantit
measur
concentr
direct
function
assay
molecul
abil
stimul
inhibit
biolog
process
signal
pathway
studi
advanc
ht
screen
technolog
lead
optim
rapid
highcont
pharmacolog
ht
screen
approach
use
evalu
solubl
adsorpt
toxic
metabol
import
drug
characterist
tradit
small
drug
molecul
synthes
join
togeth
structur
piec
set
sequenc
prepar
one
product
one
power
tool
optim
drug
discoveri
autom
highthroughput
synthesi
conduct
combinatori
approach
highthroughput
synthesi
provid
simultan
prepar
hundr
thousand
relat
drug
candid
fenniri
sucholeiki
mason
pickett
pirrung
molecular
librari
gener
screen
highthroughput
screen
assay
desir
activ
activ
molecul
identifi
ed
isol
develop
two
overal
approach
highthroughput
synthesi
combinatori
chemistri
randomli
mix
variou
reagent
mani
variat
reagent
mani
variat
reagent
b
give
random
mixtur
product
reaction
vessel
parallel
synthesi
select
conduct
mani
reaction
parallel
mani
variat
reagent
separ
multipl
reaction
vessel
mani
variat
reagent
b
give
mani
singl
product
separ
vessel
mitscher
dutta
seneci
ashton
maloney
true
combinatori
chemistri
sometim
refer
combichem
appli
method
substanti
reduc
number
synthet
oper
step
need
synthes
larg
number
compound
combichem
conduct
solid
support
resin
facilit
manipul
requir
reduc
labor
purif
multipl
product
vessel
differ
combinatori
chemistri
multipl
parallel
synthesi
procedur
appli
autom
synthet
process
address
mani
separ
reaction
vessel
need
number
oper
need
carri
synthesi
practic
convent
approach
thu
potenti
product
multipl
parallel
method
high
combinatori
chemistri
parallel
chemistri
conduct
solidphas
support
solut
facilit
purifi
cation
figur
provid
illustr
combinatori
mixandmatch
process
simpl
build
block
start
materi
amino
acid
peptid
heterocycl
small
molecul
etc
join
one
simpl
build
block
everi
possibl
combin
assign
task
autom
synthes
equip
result
rapid
creation
larg
collect
librari
larg
compound
divers
molecul
ingeni
method
devis
direct
molecul
synthes
identifi
structur
product
purifi
product
via
autom
isol
compound
coupl
highthroughput
screen
thousand
compound
gener
screen
evalu
develop
matter
week
build
block
includ
amino
acid
peptid
nucleotid
carbohydr
lipid
divers
small
molecul
scaffold
templat
mason
pickett
select
reaction
type
use
combinatori
chemistri
produc
compound
librari
found
tabl
chemic
genom
emerg
omic
technolog
discuss
develop
highthroughput
screen
highthroughput
chemistri
coupl
omic
technolog
chang
drug
discoveri
paradigm
approach
investig
target
pharmacolog
kubinyi
kubinyi
flaumenhaft
rankov
et
al
see
fig
modern
drug
discoveri
chemic
genom
sometim
call
chemogenom
gener
includ
subset
chemic
biolog
involv
screen
larg
chemic
classic
chemic
synthesi
coupl
reaction
one
start
materi
sm
one
reactant
r
wouldyield
one
product
smr
one
sever
reaction
may
run
simultan
separ
reaction
vessel
combinatori
chemic
synthesi
coupl
reaction
rang
start
materi
build
block
react
rang
reactant
build
block
yield
possibl
product
combin
sm
r
autom
reaction
may
occur
reaction
vessel
code
tag
use
separateidentifi
may
occur
small
separ
reaction
vessel
parallel
synthesi
rang
start
materi
build
block
sm
sm
n
attach
solid
support
may
contain
code
tag
autom
synthes
librari
typic
combinatori
deriv
druggabl
small
molecul
librari
cover
broad
expans
divers
space
gene
gene
product
protein
target
ie
chemic
univers
screen
target
univers
fig
basic
chemic
genom
would
occur
new
molecul
test
bioassay
develop
new
drug
target
omic
approach
came
larg
chemic
librari
typic
small
molecul
synthes
highthroughput
chemistri
part
nation
institut
health
nih
roadmap
biomed
research
nation
human
genom
research
institut
nhgri
lead
effort
offer
public
sector
biomed
research
access
librari
small
organ
molecul
use
chemic
probe
studi
cellular
pathway
greater
depth
remain
diffi
cult
predict
small
molecul
compound
effect
given
situat
research
maxim
likelihood
success
match
chemic
compound
use
research
tool
desir
therapeut
effect
systemat
screen
librari
contain
thousand
small
molecul
drug
candid
expect
correl
observ
function
analysi
molecul
gene
product
interact
genom
profi
ling
chemic
librari
may
also
yield
relev
new
target
mechan
chemic
genom
expect
critic
compon
drug
lead
identifi
cation
proof
principl
determin
select
modul
complex
enzym
system
includ
proteas
kinas
gproteincoupl
receptor
nuclear
receptor
tremend
advanc
occur
biotechnolog
sinc
watson
crick
determin
structur
dna
improv
pharmaceut
novel
therapeut
agent
uniqu
diagnost
product
new
drug
design
tool
result
escal
achiev
pharmaceut
biotechnolog
recombin
dna
technolog
hybridoma
techniqu
receiv
press
late
wealth
addit
innov
biotechnolog
approach
continu
develop
order
enhanc
pharmaceut
research
genom
proteom
transcriptom
microarray
pharmacogenomicsgenet
epigenom
person
medicin
metabonomicsmetabolom
toxicogenom
glycom
system
biolog
genet
engin
anim
highthroughput
screen
highspe
combinatori
synthesi
directli
infl
uenc
pharmaceut
scienc
well
posit
signifi
cantli
impact
modern
pharmaceut
care
applic
yet
discov
biotechnolog
continu
reshap
effect
drug
therapi
well
improv
competit
challeng
process
drug
discoveri
develop
new
medicin
agent
diagnost
pharmacist
pharmaceut
scientist
pharmaci
student
pois
take
advantag
product
techniqu
made
avail
unpreced
scope
pace
discoveri
biotechnolog
twentyfi
rst
centuri
phase
drug
action
affect
genet
variat
defi
ne
person
medicin
biomark
defi
ne
system
biolog
engin
anim
model
valuabl
pharmaceut
research
two
techniqu
commonli
use
produc
transgen
anim
knockout
mous
two
approach
highthroughput
synthesi
drug
lead
differ
answer
hgp
structur
genom
envis
proceed
increas
level
genet
resolut
detail
human
genet
linkag
map
approx
megabas
pair
mb
million
base
pair
resolut
complet
physic
map
mb
resolut
ultim
complet
dna
sequenc
approxim
billion
base
pair
pair
chromosom
human
cell
nucleu
base
pair
bp
resolut
function
genom
new
approach
genet
analysi
focus
genomewid
pattern
gene
express
mechan
gene
express
coordin
interrelationship
gene
express
cellular
environment
chang
occur
new
research
area
call
proteom
seek
defi
ne
function
correl
express
profi
le
protein
encod
within
genom
compar
base
sequenc
dna
two
individu
reveal
approxim
ident
base
differ
polymorph
scatter
throughout
genom
bestcharacter
human
polymorph
singlenucleotid
polymorph
snp
occur
approxim
everi
base
billion
base
pair
human
genom
pharmacogenet
studi
individu
genet
differ
infl
uenc
drug
action
usag
dose
detail
knowledg
patient
pharmacogenet
relat
particular
drug
therapi
may
lead
enhanc
effi
caci
greater
safeti
sometim
use
interchang
especi
pharmaci
practic
literatur
pharmacogenet
pharmacogenom
subtli
differ
pharmacogenom
introduc
addit
element
present
technic
abil
pinpoint
patientspecifi
c
dna
variat
use
genom
techniqu
overlap
fi
eld
studi
pharmacogenom
much
newer
term
correl
individu
patient
dna
variat
snp
level
variat
knowledg
rather
gene
level
variat
knowledg
respons
pharmacotherapi
fi
eld
metabonom
holist
studi
metabol
continuum
equival
level
studi
genom
proteom
biochip
known
dna
microarray
oligonucleotid
microarray
surfac
collect
hundr
thousand
immobil
dna
sequenc
oligonucleotid
grid
creat
special
equip
simultan
examin
conduct
express
analysi
genom
variat
affect
pharmacokinet
profi
le
drug
via
drug
metabol
enzym
drug
transport
protein
also
strongli
infl
uenc
pharmacodynam
profi
le
drug
via
drug
target
pharmacotherapi
inform
patient
individu
genom
proteom
inform
sometim
refer
give
right
drug
right
patient
right
dose
right
time
biomark
clinic
relev
substanc
use
indic
biolog
state
detect
concentr
chang
biomark
may
indic
particular
diseas
state
physiolog
toxic
chang
express
state
protein
biomark
may
correl
risk
progress
diseas
suscept
diseas
given
treatment
drug
safeti
profi
le
system
biolog
studi
interact
compon
biolog
system
interact
give
rise
function
behavior
system
engin
anim
model
prove
invalu
sinc
small
anim
model
diseas
often
poor
mimic
diseas
human
patient
genet
engin
predispos
anim
particular
diseas
scrutini
insert
human
gene
anim
initi
develop
clinic
relev
diseas
condit
dna
microinject
random
gene
addit
b
homolog
recombin
embryon
stem
cell
knockout
mous
also
call
gene
knockout
mous
genetarget
knockout
mous
anim
endogen
gene
genom
wildtyp
allel
specifi
calli
inactiv
replac
null
allel
two
overal
approach
highthroughput
synthesi
true
combinatori
chemistri
appli
method
substanti
reduc
number
synthet
oper
step
need
synthes
larg
number
compound
combichem
sometim
refer
conduct
solid
support
resin
facilit
need
manipul
reduc
labor
differ
combinatori
chemistri
parallel
procedur
appli
autom
synthet
process
number
oper
need
carri
synthesi
practic
convent
approach
thu
potenti
product
parallel
method
high
combinatori
chemistri
parallel
chemistri
conduct
solidphas
support
solut
zineh
pacanowski
